var title_f12_58_13216="Pancreatic pseudocyst";
var content_f12_58_13216=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F53245&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F53245&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pancreatic pseudocyst",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 358px; height: 436px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Endoscopic retrograde cholangiopancreatography (ERCP) shows a pancreatic pseudocyst with ductal comminucation. A guidewire is introduced into the cystic cavity. A pancreatic stent is placed beyond the stricture.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: ERCP in Paediatrics Practice: Diagnosis and Treatment, Isis Medical Media LTD, Oxford University Press, UK 1997. Copyright &copy;1997 Oxford University Press.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_58_13216=[""].join("\n");
var outline_f12_58_13216=null;
var title_f12_58_13217="Dermatomyositis - neck and chest";
var content_f12_58_13217=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F54230&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F54230&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Dermatomyositis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Confluent areas of violaceous erythema are present on the neck, chest, and upper arms of this patient with dermatomyositis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_58_13217=[""].join("\n");
var outline_f12_58_13217=null;
var title_f12_58_13218="Detrusor BoNT injection";
var content_f12_58_13218=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F64588&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F64588&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 495px\">",
"   <div class=\"ttl\">",
"    Botulinum toxin detrusor injection",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 475px; height: 530px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_58_13218=[""].join("\n");
var outline_f12_58_13218=null;
var title_f12_58_13219="Patient information: Hyperthyroidism (overactive thyroid) and pregnancy (The Basics)";
var content_f12_58_13219=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"7\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/85876\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/43/15024\">",
"         Thyroid and parathyroid glands",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/45/42704\">",
"          Overactive thyroid",
"         </a>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?37/1/37907\">",
"         Patient information: How to plan and prepare for a healthy pregnancy (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?22/9/22674\">",
"         Patient information: Hyperthyroidism (overactive thyroid) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?3/54/3938\">",
"         Patient information: Hypothyroidism (underactive thyroid) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?16/52/17218\">",
"         Patient information: Miscarriage (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?36/29/37331\">",
"         Patient information: Prenatal care (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?27/20/27970\">",
"         Patient information: Preterm labor (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?3/6/3172\">",
"         Patient information: Hyperthyroidism (overactive thyroid) (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?14/54/15203\">",
"         Patient information: Hypothyroidism (underactive thyroid) (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?28/8/28803\">",
"         Patient information: Miscarriage (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?34/52/35650\">",
"         Patient information: Preterm labor (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Hyperthyroidism (overactive thyroid) and pregnancy (The Basics)",
"    </div>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H600344592\">",
"      <span class=\"h1\">",
"       What is hyperthyroidism?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Hyperthyroidism is a condition that can make your heart beat fast, or make you feel shaky or anxious. It involves a gland in the neck called the thyroid (",
"      <a class=\"graphic graphic_figure graphicRef66834 \" href=\"UTD.htm?14/43/15024\">",
"       figure 1",
"      </a>",
"      ). This gland makes thyroid hormone, which controls how the body uses and stores energy.",
"     </p>",
"     <p>",
"      Hyperthyroidism is the term doctors use when the thyroid gland makes too much thyroid hormone.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H600344624\">",
"      <span class=\"h1\">",
"       What if I have hyperthyroidism and want to get pregnant?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you have hyperthyroidism and want to get pregnant, talk with your doctor or nurse before you start trying.",
"     </p>",
"     <p>",
"      Your doctor will treat your hyperthyroidism before you start trying to get pregnant. In general, hyperthyroidism in a person who is not pregnant can be treated with:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Medicines",
"       </li>",
"       <li>",
"        Radioactive iodine &ndash; This comes in a pill or liquid you swallow. It contains a small amount of radiation.",
"       </li>",
"       <li>",
"        Surgery to remove part or all of the thyroid gland",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      You and your doctor will figure out which treatment is best for you. The decision depends on many factors.",
"     </p>",
"     <p>",
"      It&rsquo;s best to treat your hyperthyroidism before you try to get pregnant. If your hyperthyroidism is treated, you won&rsquo;t have to take medicines for it during pregnancy.",
"     </p>",
"     <p>",
"      Women who are treated with radioactive iodine or surgery need to wait at least 6 months before trying to get pregnant. That way, their doctor will have enough time to check whether they are making enough thyroid hormone. Many people treated with radioactive iodine or surgery end up making too little thyroid hormone after treatment.",
"     </p>",
"     <p>",
"      This is a problem because women with too little thyroid hormone can have trouble getting pregnant. Also, if a woman has too little thyroid hormone, it can affect her baby&rsquo;s development early in pregnancy. Women who don&rsquo;t make enough thyroid hormone will need treatment.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H600344639\">",
"      <span class=\"h1\">",
"       What if I develop hyperthyroidism during pregnancy?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you develop hyperthyroidism during pregnancy, your doctor will want to know what&rsquo;s causing it. The 2 most common causes are:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        A condition called Graves&rsquo; disease (",
"        <a class=\"graphic graphic_figure graphicRef58509 \" href=\"UTD.htm?41/45/42704\">",
"         figure 2",
"        </a>",
"        )",
"       </li>",
"       <li>",
"        A condition called hCG-mediated hyperthyroidism &ndash; This is caused by a pregnancy hormone called hCG (human chorionic gonadotropin).",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      To figure out the cause, your doctor will do different blood tests.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H600344677\">",
"      <span class=\"h1\">",
"       How might hyperthyroidism affect a pregnancy?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Mild hyperthyroidism does not usually cause any problems for a woman or her baby. But severe hyperthyroidism can lead to problems if it isn&rsquo;t treated. These can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Problems in the mother, such as heart problems or a condition called preeclampsia",
"       </li>",
"       <li>",
"        Problems with the pregnancy, such as preterm labor (when labor starts too early) or miscarriage (when a pregnancy ends on its own)",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H600344692\">",
"      <span class=\"h1\">",
"       How is hyperthyroidism that develops during pregnancy treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Treatment depends on what&rsquo;s causing the hyperthyroidism and how serious it is.",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        hCG-mediated hyperthyroidism does not usually need treatment. This condition usually goes away on its own later on during pregnancy.",
"       </li>",
"       <li>",
"        Mild hyperthyroidism from Graves&rsquo; disease also does not usually need treatment. But your doctor will monitor your thyroid hormone levels by doing blood tests on a regular basis.",
"       </li>",
"       <li>",
"        Severe hyperthyroidism from Graves&rsquo; disease does need treatment. This usually involves medicines called thionamides. Your doctor will prescribe different ones at different times during your pregnancy. That&rsquo;s because some are more likely to cause birth defects at certain times during pregnancy.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H600344707\">",
"      <span class=\"h1\">",
"       Will I need tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. During pregnancy, you will have blood tests to check your thyroid hormone levels on a regular basis.",
"     </p>",
"     <p>",
"      Women with Graves&rsquo; disease will also have tests to check whether their unborn baby has hyperthyroidism. Even though it is rare, unborn babies sometimes get hyperthyroidism. These tests usually include blood tests and an ultrasound. An ultrasound uses sound waves to create pictures of your baby. If your unborn baby has hyperthyroidism, the doctor can treat it by giving you medicine.",
"     </p>",
"     <p>",
"      After pregnancy, women with Graves&rsquo; disease will have blood tests to check their thyroid hormone levels every so often. That&rsquo;s because the condition can come back later on.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H600344722\">",
"      <span class=\"h1\">",
"       Can I have a normal vaginal delivery?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Most women can have a normal vaginal delivery.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H600344737\">",
"      <span class=\"h1\">",
"       Can I breastfeed my baby?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Most women are able to breastfeed. But be sure to talk with your doctor so he or she can make sure your medicines are safe to take when breastfeeding.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H600344752\">",
"      <span class=\"h1\">",
"       Will my baby be healthy?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Chances are good that your baby will be healthy. In rare cases, though, babies born to women with Graves&rsquo; disease can also have hyperthyroidism. To check for this condition, babies have blood tests done after birth.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H600344767\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?22/9/22674?source=see_link\">",
"       Patient information: Hyperthyroidism (overactive thyroid) (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?3/54/3938?source=see_link\">",
"       Patient information: Hypothyroidism (underactive thyroid) (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?37/1/37907?source=see_link\">",
"       Patient information: How to plan and prepare for a healthy pregnancy (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?36/29/37331?source=see_link\">",
"       Patient information: Prenatal care (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?27/20/27970?source=see_link\">",
"       Patient information: Preterm labor (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?16/52/17218?source=see_link\">",
"       Patient information: Miscarriage (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?3/6/3172?source=see_link\">",
"       Patient information: Hyperthyroidism (overactive thyroid) (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?14/54/15203?source=see_link\">",
"       Patient information: Hypothyroidism (underactive thyroid) (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?34/52/35650?source=see_link\">",
"       Patient information: Preterm labor (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?28/8/28803?source=see_link\">",
"       Patient information: Miscarriage (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?12/58/13219?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 85876 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-D487AFE9F4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_58_13219=[""].join("\n");
var outline_f12_58_13219=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H600344592\">",
"      What is hyperthyroidism?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H600344624\">",
"      What if I have hyperthyroidism and want to get pregnant?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H600344639\">",
"      What if I develop hyperthyroidism during pregnancy?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H600344677\">",
"      How might hyperthyroidism affect a pregnancy?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H600344692\">",
"      How is hyperthyroidism that develops during pregnancy treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H600344707\">",
"      Will I need tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H600344722\">",
"      Can I have a normal vaginal delivery?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H600344737\">",
"      Can I breastfeed my baby?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H600344752\">",
"      Will my baby be healthy?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H600344767\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/85876\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/43/15024\">",
"      Thyroid and parathyroid glands",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/45/42704\">",
"       Overactive thyroid",
"      </a>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?37/1/37907?source=related_link\">",
"      Patient information: How to plan and prepare for a healthy pregnancy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?3/6/3172?source=related_link\">",
"      Patient information: Hyperthyroidism (overactive thyroid) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?22/9/22674?source=related_link\">",
"      Patient information: Hyperthyroidism (overactive thyroid) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?14/54/15203?source=related_link\">",
"      Patient information: Hypothyroidism (underactive thyroid) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?3/54/3938?source=related_link\">",
"      Patient information: Hypothyroidism (underactive thyroid) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?28/8/28803?source=related_link\">",
"      Patient information: Miscarriage (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?16/52/17218?source=related_link\">",
"      Patient information: Miscarriage (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?36/29/37331?source=related_link\">",
"      Patient information: Prenatal care (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?34/52/35650?source=related_link\">",
"      Patient information: Preterm labor (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/20/27970?source=related_link\">",
"      Patient information: Preterm labor (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_58_13220="Causes and treatment of hypermagnesemia";
var content_f12_58_13220=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"15\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Causes and treatment of hypermagnesemia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/58/13220/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/58/13220/contributors\">",
"     Zalman S Agus, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/58/13220/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/58/13220/contributors\">",
"     Stanley Goldfarb, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/58/13220/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/58/13220/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/58/13220/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 31, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In normal subjects, ingested magnesium is readily excreted in the urine. On a regular diet, for example, approximately 3 percent of the filtered magnesium escapes tubular reabsorption and is excreted. In contrast to most other filtered solutes, most of the filtered magnesium is reabsorbed in the cortical aspect of the thick ascending limb of Henle (50 to 60 percent), rather than the proximal tubule [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13220/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Loop reabsorption is appropriately diminished with magnesium loading, thereby allowing the excess magnesium to be excreted in the urine [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13220/abstract/1\">",
"     1",
"    </a>",
"    ]. The symptoms of hypermagnesemia and the different units that may be used to measure the plasma magnesium concentration are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/9/32914?source=see_link\">",
"     \"Symptoms of hypermagnesemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/29/470?source=see_link\">",
"     \"Regulation of magnesium balance\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CAUSES OF HYPERMAGNESEMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficiency of the renal response to a magnesium load is such that hypermagnesemia is primarily seen in two settings: when renal function is impaired",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    when a large magnesium load is given, either intravenously, orally, or as an enema.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Renal failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypermagnesemia can be seen in 10 to 15 percent of hospitalized patients, usually in the setting of renal failure. Plasma magnesium levels must rise as renal function declines, since there is no magnesium regulatory system other than urinary excretion. The typical patient with end-stage renal disease, for example, has a plasma magnesium concentration of 2 to 3",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    (2.4 to 3.6",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    or 1 to 1.5",
"    <span class=\"nowrap\">",
"     mmol/L).",
"    </span>",
"    However, severe and symptomatic hypermagnesemia can be induced when exogenous magnesium is given as antacids or laxatives in usual therapeutic dosages [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13220/abstract/3\">",
"     3",
"    </a>",
"    ]. As a result, these drugs are contraindicated in renal failure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Magnesium infusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Parenteral magnesium is commonly used to decrease neuromuscular excitability in pregnant women with severe preeclampsia or eclampsia. The usual plasma concentration achieved is 5 to 7",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    (6 to 8.4",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    or 2.5 to 3.5",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    but much higher levels can occur. There are few prospective studies of complications associated with this regimen, but maternal hypocalcemia (since hypermagnesemia can suppress the release of parathyroid hormone) and hyperkalemia and neonatal effects have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13220/abstract/4-9\">",
"     4-9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/9/32914?source=see_link\">",
"     \"Symptoms of hypermagnesemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Oral ingestion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Massive oral ingestion can on occasion exceed renal excretory capacity, particularly if there is underlying renal insufficiency. Severe hypermagnesemia with life-threatening symptoms has been described with accidental poisoning with Epsom salts (almost 100 percent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27031?source=see_link\">",
"     magnesium sulfate",
"    </a>",
"    ) in children, in laxative abusers [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13220/abstract/10\">",
"     10",
"    </a>",
"    ], and during the treatment of a variety of drug overdoses using magnesium as a cathartic [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13220/abstract/11-13\">",
"     11-13",
"    </a>",
"    ]. A fatal case of hypermagnesemia has been reported in an adult following excessive repeated Epsom salts gargles for halitosis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13220/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prospective studies of repetitive magnesium catharsis demonstrated that the usual total average dose of 960 mL of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/14/39140?source=see_link\">",
"     magnesium citrate",
"    </a>",
"    (9.22 grams) induced a mean elevation in the plasma magnesium concentration to 2.5",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    (3",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    or 1.25",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    with 10 percent of patients exceeding 3",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    (3.6",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    or 1.5",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13220/abstract/11\">",
"     11",
"    </a>",
"    ]. An elevation in the plasma magnesium concentration is much more likely in the presence of gastrointestinal disorders (active ulcer disease, gastritis, colitis) that can enhance magnesium absorption. In one retrospective study of hospital admissions, for example, eight cases of severe hypermagnesemia (plasma magnesium concentration above 6",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    or 2.5",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    were seen over a five-year period [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13220/abstract/15\">",
"     15",
"    </a>",
"    ]. These patients were elderly, taking normal amounts of magnesium as a cathartic or antacid, did not have significant renal insufficiency, but did have active gastrointestinal disease. The hypermagnesemia was unsuspected despite presentation with severe symptoms, including hypocalcemia, hypotension, and respiratory depression.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Magnesium enemas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Substantial quantities of magnesium can be absorbed from the large bowel following a magnesium enema. In normal subjects, for example, 400 to 800 mmol of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27031?source=see_link\">",
"     magnesium sulfate",
"    </a>",
"    per rectum can raise the plasma magnesium concentration to as high as 6 to 16",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    (7.2 to 19.2",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    or 3 to 8",
"    <span class=\"nowrap\">",
"     mmol/L).",
"    </span>",
"    Among patients with renal failure, the administration of a magnesium enema can be fatal [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13220/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Miscellaneous",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mild hypermagnesemia can occur in a variety of other clinical settings in selected cases. Examples include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Some cases of primary hyperparathyroidism",
"     </li>",
"     <li>",
"      Familial hypocalciuric hypercalcemia (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/51/19258?source=see_link\">",
"       \"Disorders of the calcium-sensing receptor: Familial hypocalciuric hypercalcemia and autosomal dominant hypocalcemia\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Diabetic ketoacidosis",
"     </li>",
"     <li>",
"      Hypercatabolic states, such as the tumor lysis syndrome, in which magnesium is released from the cells (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/1/19481?source=see_link\">",
"       \"Tumor lysis syndrome: Definition, pathogenesis, clinical manifestations, etiology and risk factors\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"       Lithium",
"      </a>",
"      ingestion",
"     </li>",
"     <li>",
"      Milk-alkali syndrome (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/29/27094?source=see_link\">",
"       \"The milk-alkali syndrome\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Adrenal insufficiency, perhaps due to volume depletion and hemoconcentration",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Extreme hypermagnesemia in conjunction with hypercalcemia is seen as a unique feature of Dead Sea water poisoning, since the ingested water contains very high concentrations of both magnesium and calcium [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13220/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most cases of symptomatic hypermagnesemia can be prevented by anticipation. Patients in renal failure should",
"    <strong>",
"     not",
"    </strong>",
"    receive magnesium-containing medications and patients receiving parenteral magnesium for any reason should be carefully and frequently monitored.",
"   </p>",
"   <p>",
"    If renal function is normal, cessation of magnesium therapy will allow prompt restoration of normal magnesium levels. In the absence of normal renal function, either peritoneal or hemodialysis will effectively lower the plasma magnesium concentration. Hemodialysis with its higher flow rates works more rapidly, lowering magnesium levels to the nontoxic range within 3 to 4 hours. Exchange transfusion has been effective in neonatal hypermagnesemia.",
"   </p>",
"   <p>",
"    Either form of dialysis takes at least one hour to set up. When the toxic effects of magnesium must be reversed more quickly in a patient with severe symptoms, intravenous calcium can be given as a magnesium antagonist [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13220/abstract/18\">",
"     18",
"    </a>",
"    ]. The usual dose is 100 to 200 mg of elemental calcium over 5 to 10 minutes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H322302\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hypermagnesemia is primarily seen in two settings: when renal function is impaired",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      when a large magnesium load is given, either intravenously, orally, or as an enema (see",
"      <a class=\"local\" href=\"#H2\">",
"       'Causes of hypermagnesemia'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Plasma magnesium levels rise as renal function declines, since there is no magnesium regulatory system other than urinary excretion. Severe and symptomatic hypermagnesemia can be induced when exogenous magnesium as antacids or laxatives in standard therapeutic dosages are given to patients with advanced kidney disease (eg, patients with end-stage renal disease). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Renal failure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Parenteral magnesium, which is commonly used to decrease neuromuscular excitability in pregnant women with severe preeclampsia or eclampsia, can cause hypermagnesemia. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Magnesium infusion'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Massive oral ingestion, such as with accidental poisoning in children, in laxative abusers, and during the treatment of a variety of drug overdoses using magnesium as a cathartic, can exceed renal excretory capacity, particularly if there is underlying renal insufficiency, and cause hypermagnesemia. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Oral ingestion'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Magnesium can be absorbed from the large bowel following a magnesium enema, causing moderate hypermagnesemia in normal patients, and life threatening hypermagnesemia in patients with renal failure. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Magnesium enemas'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      To prevent hypermagnesemia, patients with renal failure should",
"      <strong>",
"       not",
"      </strong>",
"      receive magnesium-containing medications and patients receiving parenteral magnesium for any reason should be carefully and frequently monitored. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If renal function is normal, cessation of magnesium therapy will allow prompt restoration of normal magnesium levels. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the absence of normal renal function, dialysis will effectively lower the plasma magnesium concentration. Exchange transfusion has been effective in neonatal hypermagnesemia. When the toxic effects of magnesium must be reversed immediately, while preparations for dialysis are being made, intravenous calcium can be given as a magnesium antagonist. The usual dose is 100 to 200 mg of elemental calcium over 5 to 10 minutes. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13220/abstract/1\">",
"      Quamme GA. Control of magnesium transport in the thick ascending limb. Am J Physiol 1989; 256:F197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13220/abstract/2\">",
"      Dai LJ, Quamme GA. Intracellular Mg2+ and magnesium depletion in isolated renal thick ascending limb cells. J Clin Invest 1991; 88:1255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13220/abstract/3\">",
"      RANDALL RE Jr, COHEN MD, SPRAY CC Jr, ROSSMEISL EC. HYPERMAGNESEMIA IN RENAL FAILURE. ETIOLOGY AND TOXIC MANIFESTATIONS. Ann Intern Med 1964; 61:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13220/abstract/4\">",
"      Monif GR, Savory J. Iatrogenic maternal hypocalcemia following magnesium sulfate therapy. JAMA 1972; 219:1469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13220/abstract/5\">",
"      Mountokalakis TH, Tsiotras S, Skopelitis P, Alivisatos J. Hypocalcemia following magnesium sulfate therapy. JAMA 1972; 221:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13220/abstract/6\">",
"      Eisenbud E, LoBue CC. Hypocalcemia after therapeutic use of magnesium sulfate. Arch Intern Med 1976; 136:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13220/abstract/7\">",
"      Cruikshank DP, Pitkin RM, Reynolds WA, et al. Effects of magnesium sulfate treatment on perinatal calcium metabolism. I. Maternal and fetal responses. Am J Obstet Gynecol 1979; 134:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13220/abstract/8\">",
"      Donovan EF, Tsang RC, Steichen JJ, et al. Neonatal hypermagnesemia: effect on parathyroid hormone and calcium homeostasis. J Pediatr 1980; 96:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13220/abstract/9\">",
"      Rasch DK, Huber PA, Richardson CJ, et al. Neurobehavioral effects of neonatal hypermagnesemia. J Pediatr 1982; 100:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13220/abstract/10\">",
"      Castelbaum AR, Donofrio PD, Walker FO, Troost BT. Laxative abuse causing hypermagnesemia, quadriparesis, and neuromuscular junction defect. Neurology 1989; 39:746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13220/abstract/11\">",
"      Woodard JA, Shannon M, Lacouture PG, Woolf A. Serum magnesium concentrations after repetitive magnesium cathartic administration. Am J Emerg Med 1990; 8:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13220/abstract/12\">",
"      Gren J, Woolf A. Hypermagnesemia associated with catharsis in a salicylate-intoxicated patient with anorexia nervosa. Ann Emerg Med 1989; 18:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13220/abstract/13\">",
"      Weber CA, Santiago RM. Hypermagnesemia. A potential complication during treatment of theophylline intoxication with oral activated charcoal and magnesium-containing cathartics. Chest 1989; 95:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13220/abstract/14\">",
"      Birrer RB, Shallash AJ, Totten V. Hypermagnesemia-induced fatality following epsom salt gargles(1). J Emerg Med 2002; 22:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13220/abstract/15\">",
"      Clark BA, Brown RS. Unsuspected morbid hypermagnesemia in elderly patients. Am J Nephrol 1992; 12:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13220/abstract/16\">",
"      Schelling JR. Fatal hypermagnesemia. Clin Nephrol 2000; 53:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13220/abstract/17\">",
"      Porath A, Mosseri M, Harman I, et al. Dead Sea water poisoning. Ann Emerg Med 1989; 18:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13220/abstract/18\">",
"      Mordes JP, Wacker WE. Excess magnesium. Pharmacol Rev 1977; 29:273.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 831 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.234.146.186-67DC1C7482-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_58_13220=[""].join("\n");
var outline_f12_58_13220=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H322302\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CAUSES OF HYPERMAGNESEMIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Renal failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Magnesium infusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Oral ingestion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Magnesium enemas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Miscellaneous",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H322302\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/51/19258?source=related_link\">",
"      Disorders of the calcium-sensing receptor: Familial hypocalciuric hypercalcemia and autosomal dominant hypocalcemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/29/470?source=related_link\">",
"      Regulation of magnesium balance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/9/32914?source=related_link\">",
"      Symptoms of hypermagnesemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/29/27094?source=related_link\">",
"      The milk-alkali syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/1/19481?source=related_link\">",
"      Tumor lysis syndrome: Definition, pathogenesis, clinical manifestations, etiology and risk factors",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_58_13221="Fluorouracil (topical): Drug information";
var content_f12_58_13221=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Fluorouracil (topical): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?40/27/41396?source=see_link\">",
"    see \"Fluorouracil (topical): Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/52/29508?source=see_link\">",
"    see \"Fluorouracil (topical): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F8100790\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Carac&reg;;",
"     </li>",
"     <li>",
"      Efudex&reg;;",
"     </li>",
"     <li>",
"      Fluoroplex&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F8100791\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Efudex&reg;;",
"     </li>",
"     <li>",
"      Fluoroplex&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F8100817\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antineoplastic Agent, Antimetabolite;",
"     </li>",
"     <li>",
"      Antineoplastic Agent, Antimetabolite (Pyrimidine Analog);",
"     </li>",
"     <li>",
"      Topical Skin Product",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F8100901\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Refer to individual protocols.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Actinic keratoses:",
"     </b>",
"     Topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Carac&trade;:",
"     </i>",
"     Apply thin film to lesions once daily for up to 4 weeks, as tolerated",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Efudex&reg;:",
"     </i>",
"     Apply to lesions twice daily for 2-4 weeks; complete healing may not be evident for 1-2 months following treatment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Fluoroplex&reg;:",
"     </i>",
"     Apply to lesions twice daily for 2-6 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Superficial basal cell carcinoma:",
"     </b>",
"     Topical: Efudex&reg; 5%: Apply to affected lesions twice daily for 3-6 weeks; treatment may be continued for up to 10-12 weeks",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F8100902\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F8100940\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, topical: 5% (40 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Carac&reg;: 0.5% (30 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Efudex&reg;: 5% (40 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Fluoroplex&reg;: 1% (30 g) [contains benzyl alcohol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, topical: 2% (10 mL); 5% (10 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Efudex&reg;: 5% (10 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F8100815\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F8100928\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     Apply 10 minutes after washing, rinsing, and drying the affected area. Apply using fingertip (wash hands immediately after application) or nonmetal applicator. Do not cover area with an occlusive dressing. Wash hands immediately after topical application of the 5% cream. Topical preparations are for external use only; not for ophthalmic, oral, or intravaginal use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F8100838\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of actinic or solar keratoses and superficial basal cell carcinomas",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F8100787\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Fluorouracil may be confused with flucytosine",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F8100847\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:0em;text-align:justify;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Systemic toxicity normally associated with parenteral administration (including neutropenia, neurotoxicity, and gastrointestinal toxicity) has been associated with topical use particularly in patients with a genetic deficiency of dihydropyrimidine dehydrogenase (DPD).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Headache, insomnia, irritability",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Alopecia, photosensitivity, pruritus, rash, scarring, telangiectasia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal:  Medicinal taste, stomatitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Leukocytosis, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Application site reactions: Allergic contact dermatitis, burning, crusting, dryness, edema, erosion, erythema, hyperpigmentation, irritation, pain, soreness, ulceration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Eye irritation (burning, watering, sensitivity, stinging, itching)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Birth defects, herpes simplex, miscarriage",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F8100843\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to fluorouracil or any component of the formulation; dihydropyrimidine dehydrogenase (DPD) enzyme deficiency; pregnancy",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F8100844\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity: May be associated with delayed-type hypersensitivity reactions. Patch testing may not be useful in the evaluation of these reactions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dihydropyrimidine dehydrogenase (DPD) enzyme deficiency: Individuals lacking DPD enzyme actiivty may exhibit severe toxicity. In cases where this deficiency has not been previously recognized, symptoms of toxicity (stomatitis, diarrhea, neutropenia, and/or neurotoxicity) or other signs of DPD deficiency should prompt immediate discontinuation and evaluation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Topical: Avoid topical application to mucous membranes due to potential for local inflammation and ulceration. The use of occlusive dressings with topical preparations may increase the severity of inflammation in nearby skin areas. Avoid exposure to ultraviolet rays during and immediately following therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F9844111\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2C9 (strong)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F8100864\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carvedilol: CYP2C9 Inhibitors (Strong) may increase the serum concentration of Carvedilol. Specifically, concentrations of the S-carvedilol enantiomer may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Substrates: CYP2C9 Inhibitors (Strong) may decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diclofenac (Systemic): CYP2C9 Inhibitors (Strong) may increase the serum concentration of Diclofenac (Systemic).  Management: Consider using a lower dose of diclofenac when used together with a strong CYP2C9 inhibitor.  Arthrotec (diclofenac and misoprostol) labeling specifically recommends limiting the total daily dose to a maximum of 50 mg twice/day.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: Fluorouracil (Topical) may increase the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gemcitabine: May increase the serum concentration of Fluorouracil (Topical).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leucovorin Calcium-Levoleucovorin: May enhance the adverse/toxic effect of Fluorouracil (Topical).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ospemifene: CYP2C9 Inhibitors (Strong) may increase the serum concentration of Ospemifene.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: Fluorouracil (Topical) may increase the serum concentration of Phenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SORAfenib: May decrease the serum concentration of Fluorouracil (Topical). SORAfenib may increase the serum concentration of Fluorouracil (Topical).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Antineoplastic Agents may enhance the anticoagulant effect of Vitamin K Antagonists. Antineoplastic Agents may diminish the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Fluorouracil (Topical) may increase the serum concentration of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F8100839\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     X (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F8100840\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects have been observed with parenteral administration in animal studies; fetal defects and miscarriages have been reported following use of topical products in humans. Use is contraindicated during pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F8100842\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F8100942\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Carac External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5% (30 g): $448.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Efudex External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5% (40 g): $276.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Fluoroplex External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1% (30 g): $462.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Fluorouracil External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5% (40 g): $247.09",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Fluorouracil External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2% (10 mL): $75.61",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5% (10 mL): $111.33",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F10961975\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Acler (AR);",
"     </li>",
"     <li>",
"      Efudix (AE, AR, AU, BE, BG, BH, CH, CN, CR, CY, DO, EG, FR, GB, GH, GT, HN, IE, IQ, IR, IT, JO, KE, KW, LB, LY, NI, NL, NO, NZ, OM, PA, PE, PL, PY, QA, SA, SV, SY, TW, TZ, UG, UY, YE, ZM);",
"     </li>",
"     <li>",
"      Efurix (BR)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F8100874\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A pyrimidine antimetabolite that interferes with DNA synthesis by blocking the methylation of deoxyuridylic acid; fluorouracil inhibits thymidylate synthetase (TS), or is incorporated into RNA. The reduced folate cofactor is required for tight binding to occur between the 5-FdUMP and TS.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F9771398\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: ~6% of a topical dose is absorbed systemically (Efudex&reg; 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak: 1 hour (Carac&reg;)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9132 Version 41.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-180.241.123.62-6A9128D992-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_58_13221=[""].join("\n");
var outline_f12_58_13221=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8100790\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8100791\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8100817\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8100901\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8100902\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8100940\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8100815\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8100928\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8100838\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8100787\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8100847\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8100843\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8100844\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9844111\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8100864\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8100839\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8100840\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8100842\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8100942\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10961975\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8100874\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9771398\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9132\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9132|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?10/42/10921?source=related_link\">",
"      Fluorouracil (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?11/24/11653?source=related_link\">",
"      Fluorouracil (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?1/10/1190?source=related_link\">",
"      Fluorouracil (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?40/27/41396?source=related_link\">",
"      Fluorouracil (topical): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/52/29508?source=related_link\">",
"      Fluorouracil (topical): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_58_13222="Membranous VSD long axis color";
var content_f12_58_13222=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1182px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/71163/Membranous_VSD_long_movie.mp4?title=Membranous+VSD+long+axis+color\" style=\"width:496px;height:384px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 566px\">",
"   <div class=\"ttl\">",
"    Membranous VSD long axis color",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 546px; height: 336px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This movie clip from a transthoracic echocardiogram shows the systolic left-to-right flow at the membranous ventricular septal defect (VSD) with color flow mapping (left hand frame). Color flow mapping also shows antegrade flow across the mitral valve (red) and the aortic valve (blue).",
"    <div class=\"footnotes\">",
"     LV: left ventricle; LA: left atrium; RV: right ventricle; AO: aorta; arrow: VSD.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_58_13222=[""].join("\n");
var outline_f12_58_13222=null;
var title_f12_58_13223="Egg allergy: Management";
var content_f12_58_13223=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Egg allergy: Management",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/58/13223/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/58/13223/contributors\">",
"     Julie Wang, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/58/13223/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/58/13223/contributors\">",
"     Scott H Sicherer, MD, FAAAAI",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/58/13223/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/58/13223/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/58/13223/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 3, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hen's egg allergy is the second most common food allergy in infants and young children (milk is the most common) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13223/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]. Egg allergies are immunologic responses to proteins in foods, and include IgE antibody-mediated allergy as well as other allergic syndromes, such as atopic dermatitis and eosinophilic esophagitis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13223/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/59/26551?source=see_link\">",
"     \"Role of allergy in atopic dermatitis (eczema)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/45/32474?source=see_link\">",
"     \"Pathogenesis, clinical manifestations, and diagnosis of eosinophilic esophagitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic reviews various aspects of management of egg allergy, including instructions about avoidance of egg protein, education in the proper management of accidental exposures, and monitoring for resolution of the allergy. Cross-reactivity between chicken egg and meat and between eggs of various birds is briefly discussed. Issues with egg-containing vaccines and lipid emulsions are also covered in this topic, although options for administration of the influenza vaccine in patients with egg allergy are discussed separately. The epidemiology, pathogenesis, clinical features, and diagnosis of egg allergy are also discussed separately. General discussions of food allergy are presented separately in appropriate topic reviews. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/9/33944?source=see_link\">",
"     \"Egg allergy: Clinical features and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/30/20967?source=see_link\">",
"     \"Influenza vaccination in individuals with egg allergy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CROSS-REACTIVITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serologic and clinical cross-reactivity with other bird eggs (turkey, duck, goose, seagull, and quail) have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13223/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. A minority of patients with allergy to egg are reactive to chicken meat as well. Chicken serum albumin (Gal d 5) is responsible for this cross-reactivity [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13223/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/63/2042?source=see_link\">",
"     \"Food allergens: Overview of clinical features and cross-reactivity\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EGG-CONTAINING VACCINES AND LIPID EMULSIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some medical products utilize egg proteins either during production or as an ingredient. These products have the potential to cause allergic reactions in egg-allergic individuals. The issues surrounding administration of influenza vaccine in patients with egg allergy are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/30/20967?source=see_link\">",
"     \"Influenza vaccination in individuals with egg allergy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/5/43097?source=see_link&amp;anchor=H8#H8\">",
"     \"Allergic reactions to vaccines\", section on 'Egg'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/5/43097?source=see_link&amp;anchor=H15#H15\">",
"     \"Allergic reactions to vaccines\", section on 'IgE-mediated reactions to specific vaccines'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/48/18185?source=see_link&amp;anchor=H15#H15\">",
"     \"Management of food allergy: Avoidance\", section on 'Food allergens in non-food items'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/13/14550?source=see_link\">",
"     yellow fever vaccine",
"    </a>",
"    is prepared in egg embryos, and allergic reactions to this vaccine have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13223/abstract/10\">",
"     10",
"    </a>",
"    ]. However, this vaccination is required for travelers entering several countries in endemic areas. In a small study, a reduced intradermal dose of the yellow fever vaccine induced protective antibody responses in egg-allergic individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13223/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/21/2394?source=see_link&amp;anchor=H3#H3\">",
"     \"Immunizations for travel\", section on 'Yellow fever vaccine'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The measles, mumps, and rubella (MMR) vaccine is NOT contraindicated for egg allergic children, although the measles vaccine is produced in a culture of chick embryo fibroblasts. Three large trials have demonstrated the safety of the MMR vaccine in egg allergic children [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13223/abstract/12-14\">",
"     12-14",
"    </a>",
"    ]. Allergic reactions to these vaccines have been primarily attributed to the gelatin component [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13223/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two other areas of concern are lipid emulsions that contain egg (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/25/17816?source=see_link\">",
"     propofol",
"    </a>",
"    and intralipid) and use of egg lysozyme, an enzyme found in egg white, in pharmaceutical products. There are case reports of anaphylaxis to these products [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13223/abstract/16-18\">",
"     16-18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/48/18185?source=see_link&amp;anchor=H15#H15\">",
"     \"Management of food allergy: Avoidance\", section on 'Food allergens in non-food items'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of egg allergy does not differ from that of other food allergies [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13223/abstract/19\">",
"     19",
"    </a>",
"    ]. It requires instructions on avoidance and education about treatment of reactions in the event of accidental exposure. It also includes monitoring for the resolution of the allergy.",
"   </p>",
"   <p>",
"    The management of food allergy in the specific settings of schools and camps is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/39/3705?source=see_link\">",
"     \"Food allergy in schools and camps\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Dietary recommendations",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Avoidance",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most straightforward approach in managing any food allergy is complete avoidance of the culprit food. Eliminating egg from the diet can be difficult and can pose nutritional as well as quality of life concerns, since egg is a ubiquitous food. Egg is an ingredient in baked goods, breaded foods, cream fillings, custards, candies, canned soups, casseroles, frostings, ice creams, lollipops, marshmallows, marzipan, pastas, salad dressings, and meat-based dishes such as meatballs or meatloaf (",
"    <a class=\"graphic graphic_table graphicRef53488 \" href=\"UTD.htm?7/56/8076\">",
"     table 1",
"    </a>",
"    ). Accidental exposures are common. In one prospective series of 500 infants aged 3 to 15 months with suspected or confirmed egg",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    milk allergy, 72 percent had an allergic reaction, most commonly to milk, egg, or peanut, during a three-year period, with an annualized reaction rate of 0.81 per year [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13223/abstract/20\">",
"     20",
"    </a>",
"    ]. Twenty one percent of these were triggered by egg, giving an annualized rate of reaction to egg of 0.17 per year. Eighty-seven percent of all reactions were due to accidental exposures. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/51/7993?source=see_link\">",
"     \"Nutritional issues in food allergy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/48/42759?source=see_link\">",
"     \"Food allergy: Impact on health-related quality of life\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/48/18185?source=see_link\">",
"     \"Management of food allergy: Avoidance\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/28/12746?source=see_link&amp;anchor=H7#H7\">",
"     \"The natural history of childhood food allergy\", section on 'Role of avoidance'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Counseling about avoidance should include discussions about the following issues:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cross-contact and hidden ingredients &mdash; Patients must be counseled about the potential for accidental exposure to food allergens via cross-contact (ie, inadvertent exposure to the allergenic food by contamination of \"safe\" foods with small amounts of the culprit food). This can happen anywhere food is served, including restaurants and bakeries. In addition, egg whites and shells are used as clarifying agents and can be found in soup stocks, consomm&eacute;s, wine, alcohol-based beverages, and coffee drinks. Egg white is also used as a wash to make bread products shiny. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/48/18185?source=see_link&amp;anchor=H5#H5\">",
"       \"Management of food allergy: Avoidance\", section on 'Skills for daily living'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Food labels &mdash; Patients must read all food labels (",
"      <a class=\"graphic graphic_table graphicRef53488 \" href=\"UTD.htm?7/56/8076\">",
"       table 1",
"      </a>",
"      ). Legislation has been enacted in the United States mandating that the ingredients labels on food packages clearly identify the presence of eight specified allergenic foods, including egg (as well as milk, tree nuts, peanuts, wheat, soybeans, fish and Crustacean shellfish) [",
"      <a class=\"abstract\" href=\"UTD.htm?12/58/13223/abstract/21\">",
"       21",
"      </a>",
"      ]. Other countries are addressing issues of food labeling as well. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/48/18185?source=see_link&amp;anchor=H6#H6\">",
"       \"Management of food allergy: Avoidance\", section on 'Food labeling'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Advisory labeling &mdash; Some products in the United States may have advisory labeling, such as \"may contain egg\". This type of labeling is not currently regulated. The risk of allergic reactions to these products is not known, and the frequency and amount of egg contamination in these products has not been studied. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/48/18185?source=see_link&amp;anchor=H9#H9\">",
"       \"Management of food allergy: Avoidance\", section on 'Advisory labeling'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Extensively heated egg &mdash; Many individuals with egg allergy can tolerate extensively heated or baked forms of egg. However, the only available diagnostic test to determine which individuals can tolerate extensively heated egg (unless it is currently in their diet) is an oral food challenge. Data suggest that tolerance to extensively heated egg is a good prognostic factor for the development of tolerance to less heated forms of egg and that including extensively heated egg in the diet may accelerate the development of tolerance [",
"      <a class=\"abstract\" href=\"UTD.htm?12/58/13223/abstract/22-24\">",
"       22-24",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/59/20409?source=see_link\">",
"       \"Oral food challenges for diagnosis and management of food allergies\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/28/12746?source=see_link&amp;anchor=H7#H7\">",
"       \"The natural history of childhood food allergy\", section on 'Role of avoidance'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Egg substitutes &mdash; Counseling should include a discussion about egg alternatives and substitutes (",
"      <a class=\"graphic graphic_table graphicRef74067 \" href=\"UTD.htm?6/18/6443\">",
"       table 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef62743 \" href=\"UTD.htm?1/62/2027\">",
"       table 3",
"      </a>",
"      ). Commercial products marketed as \"egg substitutes\" may have egg ingredients. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/51/7993?source=see_link&amp;anchor=H16#H16\">",
"       \"Nutritional issues in food allergy\", section on 'Egg allergy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Unexpected and non-food sources &mdash; Medications and vaccines may have ingredients derived from egg. Patients should ensure that the clinicians and pharmacists caring for them are aware of their egg allergy, especially before receiving any new medication or vaccine. The influenza and yellow fever vaccines may induce reactions in egg-allergic individuals. Protocols are available for the safe administration of these vaccines in egg allergic individuals. In contrast, the measles, mumps, and rubella (MMR) vaccine is well tolerated by egg allergic individuals and should be administered in the routine manner. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Egg-containing vaccines and lipid emulsions'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/30/20967?source=see_link\">",
"       \"Influenza vaccination in individuals with egg allergy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/48/18185?source=see_link&amp;anchor=H15#H15\">",
"       \"Management of food allergy: Avoidance\", section on 'Food allergens in non-food items'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Clinical scenarios",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following scenarios illustrate some of the issues involved and our management approach. Individual clinicians may decide to adopt different strategies depending upon their level of expertise and the resources available (eg, ability to perform oral food challenges).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If a patient with an allergy to egg in any or all forms or of any severity wishes to avoid all egg, we do not discourage this approach.",
"     </li>",
"     <li>",
"      We allow persons to continue to eat egg in more processed forms than what triggered their reaction(s) if they have eaten egg in these forms regularly and in the recent past (similar to passing an oral food challenge). In most cases this involves patients who reacted to lightly cooked egg (eg, scrambled egg, French toast), but have a history of tolerating extensively heated egg (eg, muffins, waffles). We generally suggest that these patients avoid more intermediate forms of cooked egg, such as",
"      <span class=\"nowrap\">",
"       meatballs/meatloaf,",
"      </span>",
"      breaded foods, casseroles, custard, mayonnaise, and hard-boiled egg.",
"      <br/>",
"      <br/>",
"      One caveat to this approach that should be discussed with patients is that it is possible that a patient may have a reaction due to ingestion of a larger amount of egg or more lightly cooked egg than usual (eg, normally tolerates egg in muffins, but has a reaction when blueberries are used in the muffins and the batter does not cook completely around the blueberries).",
"     </li>",
"     <li>",
"      We recommend that patients who have reacted to intermediately cooked or extensively heated egg avoid all forms of egg.",
"     </li>",
"     <li>",
"      An oral challenge to extensively heated egg may be performed by an allergy specialist if a patient is not currently eating egg in this form, but the patient (or parents of the patient) wishes to introduce it into the diet. Caution is needed, because severe reactions can occur from this type of oral food challenge.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Management of reactions",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Acute IgE-mediated reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Identification of individuals with IgE-mediated egg allergy is important, because these patients are at risk for severe reactions. As with other forms of food allergy, the severity of symptoms in a given individual with egg allergy may vary considerably between reactions. In addition, the severity of an initial reaction does not predict the severity of subsequent reactions. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a small study investigating whether children with egg allergy of varying severity could tolerate extensively heated forms of egg, 18 percent of children who reacted to extensively heated egg and 23 percent who reacted to lightly cooked egg required treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/63/35824?source=see_link\">",
"       epinephrine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?12/58/13223/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another series of 167 children that examined dietary advice and adherence in patients with egg allergy, the initial episode was a local reaction in 29 percent, a mild to moderate systemic reaction in 31 percent, and a severe systemic reaction in 18 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?12/58/13223/abstract/26\">",
"       26",
"      </a>",
"      ]. Twenty percent of the children in this study had a subsequent reaction to egg that was more severe than the initial event.",
"     </li>",
"     <li>",
"      Children whose only apparent clinical manifestation of food allergy is atopic dermatitis are at risk of an acute systemic reaction upon reintroduction of that food after an elimination diet [",
"      <a class=\"abstract\" href=\"UTD.htm?12/58/13223/abstract/27-29\">",
"       27-29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Children with egg allergy are more likely to develop asthma, and concomitant asthma places patients at higher risk for severe allergic reactions to foods [",
"      <a class=\"abstract\" href=\"UTD.htm?12/58/13223/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Accordingly, we suggest that individuals diagnosed with IgE-mediated egg allergy have an",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/63/35824?source=see_link\">",
"     epinephrine",
"    </a>",
"    autoinjector(s) available at all times [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13223/abstract/31\">",
"     31",
"    </a>",
"    ]. In addition, the patient should have a written anaphylaxis emergency action plan (",
"    <a class=\"graphic graphic_form graphicRef60439 \" href=\"UTD.htm?2/42/2722\">",
"     form 1",
"    </a>",
"    ). These measures are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/29/35290?source=see_link\">",
"     \"Anaphylaxis: Rapid recognition and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Delayed gastrointestinal reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of children with eosinophilic esophagitis and food-protein induced enteropathy caused by egg and other foods is presented in the specific topic reviews. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/16/44297?source=see_link\">",
"     \"Treatment of eosinophilic esophagitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/52/34631?source=see_link\">",
"     \"Food protein-induced proctitis/colitis and enteropathy of infancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Monitoring for resolution",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with egg allergy should be monitored for resolution of the allergy, since most will outgrow the allergy in childhood. The steps to take to determine if an allergy has resolved are covered in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/9/33944?source=see_link&amp;anchor=H9#H9\">",
"     \"Egg allergy: Clinical features and diagnosis\", section on 'Natural course'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/28/12746?source=see_link&amp;anchor=H8#H8\">",
"     \"The natural history of childhood food allergy\", section on 'Monitoring the food-allergic child'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/28/12746?source=see_link&amp;anchor=H16#H16\">",
"     \"The natural history of childhood food allergy\", section on 'Natural history of specific allergies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Management of younger siblings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Parents often inquire about what measures to take to prevent egg allergy (eg, maternal avoidance during pregnancy and lactation) and when to introduce egg in a younger sibling of a child with egg allergy. In these cases, avoidance of egg is not recommended for nursing mothers, nor is delayed introduction of egg beyond six months of age, unless the infant is showing signs of allergic disease. These issues are discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/42/43689?source=see_link&amp;anchor=H38#H38\">",
"     \"Pathogenesis of food allergy\", section on 'Genetics'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/37/25175?source=see_link&amp;anchor=H12#H12\">",
"     \"Introducing formula and solid foods to infants at risk for allergic disease\", section on 'Introduction of solid foods to high risk infants'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/57/17304?source=see_link\">",
"     \"The impact of breastfeeding on the development of allergic disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/41/20119?source=see_link\">",
"     \"Primary prevention of allergic disease: Maternal avoidance diets in pregnancy and lactation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     FUTURE TREATMENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no treatments that can cure or provide long-term remission from food allergy. However, several treatment strategies are under investigation. These approaches are either allergen-specific or aimed at modulating the overall allergic response. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/1/44057?source=see_link\">",
"     \"Future therapies for food allergy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?28/47/29429?source=see_link\">",
"       \"Patient information: Food allergy symptoms and diagnosis (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?34/35/35379?source=see_link\">",
"       \"Patient information: Food allergy treatment and avoidance (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Management of egg allergy includes instructions about avoidance of egg-containing products, education in the proper management of accidental exposures, and monitoring for resolution of the allergy. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Management'",
"      </a>",
"      above.) and (",
"      <a class=\"graphic graphic_table graphicRef53488 \" href=\"UTD.htm?7/56/8076\">",
"       table 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef74067 \" href=\"UTD.htm?6/18/6443\">",
"       table 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef62743 \" href=\"UTD.htm?1/62/2027\">",
"       table 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_form graphicRef60439 \" href=\"UTD.htm?2/42/2722\">",
"       form 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      We recommend that",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/63/35824?source=see_link\">",
"       epinephrine",
"      </a>",
"      autoinjectors be prescribed for all patients with a history of anaphylactic reactions to egg (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). We suggest that epinephrine autoinjectors be prescribed for all patients with milder IgE-mediated reactions to egg (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Acute IgE-mediated reactions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Vaccines and medications may contain egg proteins that can induce allergic reactions. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Egg-containing vaccines and lipid emulsions'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Avoidance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The MMR vaccine is well tolerated and is not contraindicated in egg allergic patients. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Egg-containing vaccines and lipid emulsions'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13223/abstract/1\">",
"      Sicherer SH, Sampson HA. 9. Food allergy. J Allergy Clin Immunol 2006; 117:S470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13223/abstract/2\">",
"      Eggesb&oslash; M, Botten G, Halvorsen R, Magnus P. The prevalence of allergy to egg: a population-based study in young children. Allergy 2001; 56:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13223/abstract/3\">",
"      Sampson HA. Role of immediate food hypersensitivity in the pathogenesis of atopic dermatitis. J Allergy Clin Immunol 1983; 71:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13223/abstract/4\">",
"      Sampson HA, McCaskill CC. Food hypersensitivity and atopic dermatitis: evaluation of 113 patients. J Pediatr 1985; 107:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13223/abstract/5\">",
"      Sampson HA, Scanlon SM. Natural history of food hypersensitivity in children with atopic dermatitis. J Pediatr 1989; 115:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13223/abstract/6\">",
"      Hill DJ, Hosking CS, de Benedictis FM, et al. Confirmation of the association between high levels of immunoglobulin E food sensitization and eczema in infancy: an international study. Clin Exp Allergy 2008; 38:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13223/abstract/7\">",
"      Langeland T. A clinical and immunological study of allergy to hen's egg white. VI. Occurrence of proteins cross-reacting with allergens in hen's egg white as studied in egg white from turkey, duck, goose, seagull, and in hen egg yolk, and hen and chicken sera and flesh. Allergy 1983; 38:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13223/abstract/8\">",
"      Alessandri C, Calvani M Jr, Rosengart L, Madella C. Anaphylaxis to quail egg. Allergy 2005; 60:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13223/abstract/9\">",
"      Quirce S, Mara&ntilde;&oacute;n F, Umpi&eacute;rrez A, et al. Chicken serum albumin (Gal d 5*) is a partially heat-labile inhalant and food allergen implicated in the bird-egg syndrome. Allergy 2001; 56:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13223/abstract/10\">",
"      Kelso JM, Mootrey GT, Tsai TF. Anaphylaxis from yellow fever vaccine. J Allergy Clin Immunol 1999; 103:698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13223/abstract/11\">",
"      Roukens AH, Vossen AC, van Dissel JT, Visser LG. Reduced intradermal test dose of yellow fever vaccine induces protective immunity in individuals with egg allergy. Vaccine 2009; 27:2408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13223/abstract/12\">",
"      Fasano MB, Wood RA, Cooke SK, Sampson HA. Egg hypersensitivity and adverse reactions to measles, mumps, and rubella vaccine. J Pediatr 1992; 120:878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13223/abstract/13\">",
"      Freigang B, Jadavji TP, Freigang DW. Lack of adverse reactions to measles, mumps, and rubella vaccine in egg-allergic children. Ann Allergy 1994; 73:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13223/abstract/14\">",
"      Aickin R, Hill D, Kemp A. Measles immunisation in children with allergy to egg. BMJ 1994; 309:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13223/abstract/15\">",
"      Pool V, Braun MM, Kelso JM, et al. Prevalence of anti-gelatin IgE antibodies in people with anaphylaxis after measles-mumps rubella vaccine in the United States. Pediatrics 2002; 110:e71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13223/abstract/16\">",
"      Hofer KN, McCarthy MW, Buck ML, Hendrick AE. Possible anaphylaxis after propofol in a child with food allergy. Ann Pharmacother 2003; 37:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13223/abstract/17\">",
"      Buchman AL, Ament ME. Comparative hypersensitivity in intravenous lipid emulsions. JPEN J Parenter Enteral Nutr 1991; 15:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13223/abstract/18\">",
"      Artesani MC, Donnanno S, Cavagni G, et al. Egg sensitization caused by immediate hypersensitivity reaction to drug-containing lysozyme. Ann Allergy Asthma Immunol 2008; 101:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13223/abstract/19\">",
"      Clark AT, Skypala I, Leech SC, et al. British Society for Allergy and Clinical Immunology guidelines for the management of egg allergy. Clin Exp Allergy 2010; 40:1116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13223/abstract/20\">",
"      Fleischer DM, Perry TT, Atkins D, et al. Allergic reactions to foods in preschool-aged children in a prospective observational food allergy study. Pediatrics 2012; 130:e25.",
"     </a>",
"    </li>",
"    <li>",
"     United States Food Allergen Labeling and Consumer Protection Act of 2004.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13223/abstract/22\">",
"      Nowak-Wegrzyn AH, Leonard SA, Bencharitiwong R, et al. Follow-up of the heated egg (HE) diet trial. J Allergy Clin Immunol 2011; 127:AB25 (Abstract).",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13223/abstract/23\">",
"      Clark A, Islam S, King Y, et al. A longitudinal study of resolution of allergy to well-cooked and uncooked egg. Clin Exp Allergy 2011; 41:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13223/abstract/24\">",
"      Leonard SA, Sampson HA, Sicherer SH, et al. Dietary baked egg accelerates resolution of egg allergy in children. J Allergy Clin Immunol 2012; 130:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13223/abstract/25\">",
"      Lemon-Mul&eacute; H, Sampson HA, Sicherer SH, et al. Immunologic changes in children with egg allergy ingesting extensively heated egg. J Allergy Clin Immunol 2008; 122:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13223/abstract/26\">",
"      Allen CW, Kemp AS, Campbell DE. Dietary advice, dietary adherence and the acquisition of tolerance in egg-allergic children: a 5-yr follow-up. Pediatr Allergy Immunol 2009; 20:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13223/abstract/27\">",
"      David TJ. Anaphylactic shock during elimination diets for severe atopic eczema. Arch Dis Child 1984; 59:983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13223/abstract/28\">",
"      Ito K, Morishita M, Ito A, et al. [Immediate type food hypersensitivity associated with atopic dermatitis in children]. Arerugi 2004; 53:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13223/abstract/29\">",
"      Eller E, Kjaer HF, H&oslash;st A, et al. Food allergy and food sensitization in early childhood: results from the DARC cohort. Allergy 2009; 64:1023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13223/abstract/30\">",
"      Tariq SM, Matthews SM, Hakim EA, Arshad SH. Egg allergy in infancy predicts respiratory allergic disease by 4 years of age. Pediatr Allergy Immunol 2000; 11:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13223/abstract/31\">",
"      Sampson HA, Mu&ntilde;oz-Furlong A, Campbell RL, et al. Second symposium on the definition and management of anaphylaxis: summary report--Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin Immunol 2006; 117:391.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2390 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-203.80.222.8-3836C529BC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_58_13223=[""].join("\n");
var outline_f12_58_13223=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CROSS-REACTIVITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EGG-CONTAINING VACCINES AND LIPID EMULSIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Dietary recommendations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Avoidance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Clinical scenarios",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Management of reactions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Acute IgE-mediated reactions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Delayed gastrointestinal reactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Monitoring for resolution",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Management of younger siblings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      FUTURE TREATMENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/2390\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/2390|Form\">",
"      <a href=\"#\" title=\"FORMS\">",
"       FORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_form\" href=\"UTD.htm?2/42/2722\" title=\"form 1\">",
"      Anaphylaxis action plan",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/2390|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/56/8076\" title=\"table 1\">",
"      Ingredient label terms for egg",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/18/6443\" title=\"table 2\">",
"      Egg alternatives",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/62/2027\" title=\"table 3\">",
"      Egg substitutes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/5/43097?source=related_link\">",
"      Allergic reactions to vaccines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/29/35290?source=related_link\">",
"      Anaphylaxis: Rapid recognition and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/9/33944?source=related_link\">",
"      Egg allergy: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/63/2042?source=related_link\">",
"      Food allergens: Overview of clinical features and cross-reactivity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/39/3705?source=related_link\">",
"      Food allergy in schools and camps",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/48/42759?source=related_link\">",
"      Food allergy: Impact on health-related quality of life",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/52/34631?source=related_link\">",
"      Food protein-induced proctitis/colitis and enteropathy of infancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/1/44057?source=related_link\">",
"      Future therapies for food allergy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/21/2394?source=related_link\">",
"      Immunizations for travel",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/30/20967?source=related_link\">",
"      Influenza vaccination in individuals with egg allergy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/37/25175?source=related_link\">",
"      Introducing formula and solid foods to infants at risk for allergic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/48/18185?source=related_link\">",
"      Management of food allergy: Avoidance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/51/7993?source=related_link\">",
"      Nutritional issues in food allergy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/59/20409?source=related_link\">",
"      Oral food challenges for diagnosis and management of food allergies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/42/43689?source=related_link\">",
"      Pathogenesis of food allergy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/45/32474?source=related_link\">",
"      Pathogenesis, clinical manifestations, and diagnosis of eosinophilic esophagitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?28/47/29429?source=related_link\">",
"      Patient information: Food allergy symptoms and diagnosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?34/35/35379?source=related_link\">",
"      Patient information: Food allergy treatment and avoidance (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/41/20119?source=related_link\">",
"      Primary prevention of allergic disease: Maternal avoidance diets in pregnancy and lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/59/26551?source=related_link\">",
"      Role of allergy in atopic dermatitis (eczema)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/57/17304?source=related_link\">",
"      The impact of breastfeeding on the development of allergic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/28/12746?source=related_link\">",
"      The natural history of childhood food allergy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/16/44297?source=related_link\">",
"      Treatment of eosinophilic esophagitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_58_13224="Management of Down syndrome";
var content_f12_58_13224=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of Down syndrome",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/58/13224/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/58/13224/contributors\">",
"     Kathryn K Ostermaier, MD, FAAP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/58/13224/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/58/13224/contributors\">",
"     Helen V Firth, DM, FRCP, DCH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/58/13224/contributors\">",
"     Jan E Drutz, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/58/13224/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/58/13224/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/58/13224/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 8, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Down syndrome (DS) is the most common chromosome abnormality among liveborn infants. It is the most frequent form of intellectual disability (mental retardation) caused by a microscopically demonstrable chromosomal aberration.",
"   </p>",
"   <p>",
"    The Committee on Genetics of the American Academy of Pediatrics (AAP) has provided recommendations to assist clinicians in the care of children with DS [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13224/abstract/1\">",
"     1",
"    </a>",
"    ]. These recommendations are available at",
"    <span class=\"nowrap\">",
"     pediatrics.aappublications.org/content/128/2/393.full.pdf+html.",
"    </span>",
"    The recommendations for medical evaluation are summarized in Appendix 1 of this document. Management requires an organized approach to the initial and ongoing evaluation and monitoring for associated abnormalities and prevention of common disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13224/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The management and life expectancy of children with Down syndrome is presented here. The epidemiology, clinical features, and diagnosis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/27/22969?source=see_link&amp;anchor=H4#H4\">",
"     \"Overview of prenatal screening and diagnosis of Down syndrome\", section on 'Candidates for prenatal screening and diagnosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/0/23562?source=see_link&amp;anchor=H9#H9\">",
"     \"Congenital cytogenetic abnormalities\", section on 'Trisomy 21 (Down syndrome)'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/15/26874?source=see_link\">",
"     \"Clinical features and diagnosis of Down syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    General issues related to management of adults with intellectual disability are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/26/12713?source=see_link\">",
"     \"Primary care of the adult with intellectual disability (mental retardation)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GROWTH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anthropometric measurements should be plotted on standard National Center for Health Statistics or World Health Organization growth charts. Patients with DS should be monitored for disturbances of growth associated with other disorders, such as hypothyroidism or celiac disease, and for excessive weight gain. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/14/31976?source=see_link\">",
"     \"Measurement of growth in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Obesity prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;A goal of growth monitoring is the prevention of obesity. Interventions beginning at 24 months of age should include attention to diet and promotion of physical activity. Caloric intake should be less than recommended for age in typical individuals, and supplemental vitamins and minerals should be provided [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13224/abstract/4\">",
"     4",
"    </a>",
"    ]. Calcium and vitamin D intake should be monitored closely to minimize bone loss, since adults with DS have lower bone mineral density than controls [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13224/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CARDIAC DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;All newborns with DS should be evaluated for congenital heart disease in consultation with a pediatric cardiologist. An echocardiogram is recommended to detect abnormalities that may not be symptomatic or apparent on physical examination. Continued clinical cardiac evaluation is needed because of the high risk of mitral valve prolapse and aortic regurgitation in adolescents and young adults [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13224/abstract/2\">",
"     2",
"    </a>",
"    ]. In a large retrospective cohort study of congenital heart surgery, patients with DS had similar mortality, but higher morbidity, compared with patients without DS [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13224/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/44/33482?source=see_link\">",
"     \"Congenital heart disease (CHD) in the newborn: Presentation and screening for critical CHD\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/1/38936?source=see_link\">",
"     \"Management and outcome of isolated atrial septal defects in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/55/34680?source=see_link\">",
"     \"Management of isolated ventricular septal defects in infants and children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/42/33448?source=see_link\">",
"     \"Management of patent ductus arteriosus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/7/28794?source=see_link\">",
"     \"Overview of the management of tetralogy of Fallot\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     HEARING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Newborns should have a newborn hearing screen with brainstem auditory evoked response (BAER) or otoacoustic emission (OAE) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13224/abstract/1\">",
"     1",
"    </a>",
"    ]. Infants with DS should have repeat hearing screening at six months of age. Hearing should be evaluated regularly throughout childhood, typically every six months until four to five years of age and then yearly. Any child who fails screening should be referred to an otolaryngologist for further evaluation and management. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/13/27865?source=see_link\">",
"     \"Screening the newborn for hearing loss\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/19/44344?source=see_link\">",
"     \"Evaluation of hearing impairment in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/13/43225?source=see_link&amp;anchor=H9#H9\">",
"     \"Screening tests in children and adolescents\", section on 'Hearing screen'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Children should be evaluated and treated for otitis media, which occurs commonly [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13224/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/60/29642?source=see_link\">",
"     \"Acute otitis media in children: Epidemiology, microbiology, clinical manifestations, and complications\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     OPHTHALMOLOGIC DISORDERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;An ophthalmologic assessment should be performed in the newborn period or at least before six months of age to detect strabismus, nystagmus, and cataracts. The risk of refractive errors is approximately 50 percent between three and five years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13224/abstract/1\">",
"     1",
"    </a>",
"    ]. Affected children should have annual assessments of vision. Unaffected children should be examined annually before age five years to detect refractive errors that may occur during childhood, and every two years after age five (every three years after age 13) to screen for disorders, including keratoconus and lens opacities, that may develop in adolescents or adults. The examination should be performed by a pediatric ophthalmologist or ophthalmologist with expertise in infants with disabilities. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/59/24505?source=see_link\">",
"     \"Visual development and vision assessment in infants and children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/8/34951?source=see_link&amp;anchor=H8#H8\">",
"     \"Evaluation and management of strabismus in children\", section on 'Evaluation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/23/34165?source=see_link\">",
"     \"Overview of nystagmus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/14/22761?source=see_link\">",
"     \"Cataract in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     THYROID FUNCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thyroid function testing should be obtained in the newborn period. The AAP recommends that screening should be repeated at 6 and 12 months, and then annually [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13224/abstract/1\">",
"     1",
"    </a>",
"    ]. However, there is debate regarding the optimal frequency of laboratory screening [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13224/abstract/8-11\">",
"     8-11",
"    </a>",
"    ]. Height and weight should be measured yearly since the combination of deceleration of linear growth associated with weight gain is a sensitive indicator of hypothyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13224/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/39/2682?source=see_link\">",
"     \"Clinical features and detection of congenital hypothyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CELIAC DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Screening for symptoms of celiac disease should begin at one year of age [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13224/abstract/1\">",
"     1",
"    </a>",
"    ]. Laboratory screening is recommended if signs or symptoms develop. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/3/37946?source=see_link\">",
"     \"Clinical manifestations and diagnosis of celiac disease in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     HEMATOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A complete blood count and differential should be obtained at birth to evaluate for myeloproliferative disorders and polycythemia. Infants with transient myeloproliferative disorders should be followed with a complete blood count and differential every three months until three years of age and then every six months until six years of age. This monitoring protocol is modified from that used in the prospective study of transient leukemia in DS conducted by the Pediatric Oncology Group [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13224/abstract/12\">",
"     12",
"    </a>",
"    ]. Children with DS are at increased risk for leukemia. Thus, there should be vigilance for signs of leukemia, such as anemia, increased infections, and excessive bruising. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/15/26874?source=see_link&amp;anchor=H14#H14\">",
"     \"Clinical features and diagnosis of Down syndrome\", section on 'Hematologic disorders'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/6/36968?source=see_link\">",
"     \"Neonatal polycythemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/58/4009?source=see_link\">",
"     \"Overview of the presentation and classification of acute lymphoblastic leukemia in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A hemoglobin level should be obtained annually from 1 to 13 years of age to screen for anemia [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13224/abstract/1\">",
"     1",
"    </a>",
"    ]. The anemia is usually due to iron deficiency secondary to the restricted diet that many children with Down syndrome develop as a result of delayed oral motor skills and dysphagia. However, anemia may also be a sign of leukemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     PERIODONTAL DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Periodontal disease is common in children and adults with DS and involves inflammation, periods of acute infection, and pain [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13224/abstract/13\">",
"     13",
"    </a>",
"    ]. The increased frequency is thought to be due in part to alterations in mouth flora, with a higher frequency of Actinobacillus actinomycetemcomitans compared to controls [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13224/abstract/14\">",
"     14",
"    </a>",
"    ]. Overlapping teeth, poor oral hygiene, and immune deficiency may also play a role [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13224/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/45/32471?source=see_link&amp;anchor=H10#H10\">",
"     \"Overview of gingivitis and periodontitis in children and adolescents\", section on 'Periodontitis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/60/8137?source=see_link&amp;anchor=H12#H12\">",
"     \"Systemic conditions associated with periodontal disease in children\", section on 'Down syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Routine brushing should be encouraged. Dental visits are recommended every six months. Orthodontic problems, which occur in the majority of DS patients, should be evaluated and treated if possible. However, the cooperation necessary for many orthodontic procedures may make them impractical in this population.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     ATLANTOAXIAL INSTABILITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The American Academy of Pediatrics Committee on Genetics and the AAP Committee on Sports Medicine and Fitness recommend careful neurologic evaluation for signs and symptoms consistent with spinal cord injury (eg, loss of motor skills, loss of bowel or bladder control, neck pain, neck stiffness) as the most important clinical predictor of symptomatic atlantoaxial instability and dislocation [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13224/abstract/1,16\">",
"     1,16",
"    </a>",
"    ]. The evaluating clinician should take a careful history and perform a thorough physical examination, looking for evidence of neurologic involvement. This clinical screening process should be done at least annually. Caution regarding contact sports and trampoline use should be discussed with families.",
"   </p>",
"   <p>",
"    The AAP Committee on Genetics recommends obtaining lateral plain cervical spine radiographs in the neutral position with odontoid and anterior-posterior (A-P) views to examine for evidence of atlantoaxial instability (AAI) or subluxation in patients with myopathic signs or symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13224/abstract/1\">",
"     1",
"    </a>",
"    ]. The patient should be placed in a collar and referred immediately to a pediatric neurosurgeon or pediatric orthopedic surgeon if significant radiographic abnormalities are noted. Flexion and extension radiographs may be performed prior to referral if no significant radiographic abnormalities are present. The AAP Committee on Sports Medicine and Fitness recommends that symptomatic children have an MRI to clarify the extent of spinal cord compression, and that appropriate surgical consultation be obtained to evaluate the need for definitive treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13224/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nearly all people with AAI who have suffered a catastrophic injury to the spinal cord have had preceding neurologic symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13224/abstract/16\">",
"     16",
"    </a>",
"    ]. Asymptomatic AAI is relatively uncommon, occurring in only 2.6 percent of patients with Down syndrome in one study [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13224/abstract/17\">",
"     17",
"    </a>",
"    ]. Despite this, the Special Olympics requires screening neck radiographs in children with DS before participation. Children who are found to have AAI on these radiographs but who lack neurologic symptoms should be followed closely with repeat neurologic examinations (at least annually) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13224/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     BEHAVIOR AND PSYCHIATRIC PROBLEMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Assessment and treatment of behavior and psychiatric problems should be expeditious and should include evaluation of the problem at school and at home, behavior management techniques, and medication as needed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/29/19928?source=see_link\">",
"     \"Developmental and behavioral screening tests in primary care\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/18/26922?source=see_link&amp;anchor=H14#H14\">",
"     \"Attention deficit hyperactivity disorder in children and adolescents: Clinical features and evaluation\", section on 'Evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SLEEP APNEA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with DS have an increased risk of obstructive sleep apnea because of soft tissue and skeletal alterations that lead to upper airway obstruction. Symptoms related to sleep apnea (snoring, restless sleep, and sleep position) should be discussed at health supervision visits beginning at age one year and continuing throughout childhood [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13224/abstract/18\">",
"     18",
"    </a>",
"    ]. Polysomnography is recommended in all children with DS by four years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13224/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/36/9801?source=see_link\">",
"     \"Mechanisms and predisposing factors for sleep related breathing disorders in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/38/44649?source=see_link\">",
"     \"Evaluation of suspected obstructive sleep apnea in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/17/40217?source=see_link\">",
"     \"Management of obstructive sleep apnea in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4399687\">",
"    <span class=\"h1\">",
"     FERTILITY AND REPRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ages for the onset and completion of puberty are typical for individuals with DS. However, the mean stretched penile length and the mean testicular volumes are significantly below average among adult men with DS compared with normal men. Fertility is impaired in individuals with DS, most likely secondary to primary gonadal deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13224/abstract/19\">",
"     19",
"    </a>",
"    ]. Most published data, however, suggests that 15 to 30 percent of women with DS are capable of becoming pregnant and their risk of having a child with DS is about 50 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13224/abstract/20\">",
"     20",
"    </a>",
"    ]. Offspring without trisomy 21 seem to have an increased risk for other congenital and developmental abnormalities. Limited research also suggests that women with DS may have an increased risk for miscarriages, premature births, and difficult labor [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13224/abstract/21\">",
"     21",
"    </a>",
"    ]. Men with DS are generally thought to be infertile. However, there have been various published case reports of men with DS fathering children [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13224/abstract/22-24\">",
"     22-24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Individuals with various disabilities are at an increased risk for sexual abuse. It is important for parents to discuss matters of sexuality, social skills training, and measures to prevent pregnancy routinely with older children and adults with DS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2688753\">",
"    <span class=\"h1\">",
"     ALZHEIMER DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dementia that resembles Alzheimer disease is more common and occurs at an earlier age in patients with DS. A medical evaluation should be performed, including testing for thyroid disease, when the diagnosis of Alzheimer disease is considered. Possible depression should also be excluded. The diagnosis and treatment of dementia, including in patients with DS, is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/15/26874?source=see_link&amp;anchor=H31550131#H31550131\">",
"     \"Clinical features and diagnosis of Down syndrome\", section on 'Dementia/Alzheimer disease'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/25/28057?source=see_link\">",
"     \"Evaluation of cognitive impairment and dementia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/4/33865?source=see_link\">",
"     \"Treatment of dementia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     LIFE EXPECTANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Life expectancy in DS is shorter than that in the general population or in individuals with other causes of intellectual disability. However, survival has improved substantially [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13224/abstract/25-27\">",
"     25-27",
"    </a>",
"    ]. This is illustrated by a study using United States (US) death certificates, in which the median age at death increased from 25 to 49 years from 1983 to 1997 [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13224/abstract/25\">",
"     25",
"    </a>",
"    ]. Compared to death certificates without a diagnosis of DS, those with DS were more likely to list disorders including congenital heart defects, dementia, hypothyroidism, or leukemia. The improved survival was thought to be due to increased placement of infants in homes rather than institutions and to changes in treatment for common causes of death, especially congenital heart disease.",
"   </p>",
"   <p>",
"    In a retrospective cohort study conducted on 16,506 infants with DS born in the US between 1983 and 2003, the overall 1-month and 1-, 5-, and 20-year survival probabilities were 98, 93, 91, and 88 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13224/abstract/28\">",
"     28",
"    </a>",
"    ]. Survival improved modestly over the course of the study in all but the neonatal period.",
"   </p>",
"   <p>",
"    In the study using death certificate data, malignancies other than leukemia were much less frequent in those with than without DS (standardized mortality odds ratio 0.07) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13224/abstract/25\">",
"     25",
"    </a>",
"    ]. Possible mechanisms suggested for the low rate of cancer include tumor suppressor genes on chromosome 21, a slower rate of replication or higher rate of apoptosis in DS cells, or less exposure to environmental risks.",
"   </p>",
"   <p>",
"    Predictors of survival in DS may include race, gender, birth weight, gestational age at birth, and presence of heart defects and other structural anomalies [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13224/abstract/25,28-30\">",
"     25,28-30",
"    </a>",
"    ]. In the death certificate study noted above, the median age at death was lower among blacks than whites [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13224/abstract/25\">",
"     25",
"    </a>",
"    ]. In contrast to the greater longevity of females in most populations, males with DS appear to have a survival advantage [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13224/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. In a series from Western Australia, life expectancy was 58.6 years for the population, and 3.3 years longer for males than females [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13224/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2067895\">",
"    <span class=\"h1\">",
"     BASIC SCIENCE RESEARCH AND FUTURE TREATMENT OPTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The development of DS mouse models has provided an opportunity to study emerging pharmacotherapies that target intellectual disabilities common in DS [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13224/abstract/33-35\">",
"     33-35",
"    </a>",
"    ]. The overexpression of many genes found on the 21",
"    <sup>",
"     st",
"    </sup>",
"    chromosome contributes to learning deficits. Research has focused on hippocampus function related to memory and learning. Areas of interest include specific gamma-aminobutyric acid (GABA) receptor inhibitors, N-methyl-D-aspartic (NMDA) receptor antagonists, and hippocampal dentate gyrus neurogenesis. Preliminary basic science research shows medications such as pentylenetetrazole (PTZ),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/16/24837?source=see_link\">",
"     memantine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"     fluoxetine",
"    </a>",
"    may enhance learning in the DS mouse model. Further studies and clinical trials are needed to show efficacy and safety of these medications in children with DS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     ALTERNATIVE TREATMENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oxidative stress, the imbalance between production and removal of oxygen-derived free radicals, may contribute to some features of DS, such as decreased immune function, premature aging, impaired mental function, and malignancy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13224/abstract/36\">",
"     36",
"    </a>",
"    ]. In particular, the activity of superoxide dismutase (the gene for which is located on chromosome 21) is increased [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13224/abstract/37\">",
"     37",
"    </a>",
"    ]. Superoxide dismutase is usually regarded as a protective enzyme since it scavenges free superoxide molecules. However, in DS the",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/41/41617?source=see_link\">",
"     hydrogen peroxide",
"    </a>",
"    generated by superoxide dismutase-1 may become toxic in the presence of ferrous iron (Fe2+); it forms the highly toxic hydroxyl radical (OH), which can result in profound cellular damage [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13224/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Supplementation with antioxidant nutrients has been proposed as potential therapy for DS. Treatments studied include supplementation with zinc,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/37/13907?source=see_link\">",
"     selenium",
"    </a>",
"    , megavitamins and minerals, vitamin A, vitamin B6, 5-hydroxytryptamine, coenzyme Q10, and targeted nutritional intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13224/abstract/36,39,40\">",
"     36,39,40",
"    </a>",
"    ]. These studies have methodologic flaws and provide no convincing evidence that nutritional supplementation improves outcomes in DS. One randomized controlled trial evaluated psychomotor and language development in 156 infants treated for 18 months with daily oral supplementation with one of four programs: antioxidants (selenium, zinc, vitamin A, vitamin E, vitamin C), folinic acid, antioxidants and folinic acid combined, or placebo. This trial found no significant differences between the groups [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13224/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     COUNSELING AND RESOURCES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Counseling may begin when a prenatal diagnosis of DS is made or suspected [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13224/abstract/1\">",
"     1",
"    </a>",
"    ]. The discussion should include the wide range of variability in manifestations and prognosis. Medical and educational treatments and interventions should be discussed. Initial referrals should be made to early intervention, informative publications [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13224/abstract/41\">",
"     41",
"    </a>",
"    ], parent groups, and advocacy groups. In the early teen years, discussion and plans for transition to adulthood should include employment, place of residence, and leisure activities.",
"   </p>",
"   <p>",
"    Internet resources for parents and patients include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The Association for Children with Down Syndrome &mdash;",
"      <a class=\"external\" href=\"file://www.acds.org/\">",
"       www.acds.org",
"      </a>",
"     </li>",
"     <li>",
"      National Down Syndrome Congress &mdash;",
"      <a class=\"external\" href=\"file://www.ndsccenter.org/\">",
"       www.ndsccenter.org",
"      </a>",
"     </li>",
"     <li>",
"      National Down Syndrome Society &mdash;",
"      <a class=\"external\" href=\"file://www.ndss.org/\">",
"       www.ndss.org",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A brochure entitled, \"Your baby and Down syndrome: Answers to questions you might have,\" available in English and Spanish, can be downloaded from the National Down Syndrome Society website.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?33/28/34242?source=see_link\">",
"       \"Patient information: Down syndrome (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?28/45/29394?source=see_link\">",
"       \"Patient information: Down syndrome (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2085169\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Management of Down syndrome (DS) requires an organized approach to ongoing evaluation and monitoring for associated abnormalities and prevention of common disorders. The Committee on Genetics of the American Academy of Pediatrics (AAP) has provided recommendations to assist clinicians in the care of children with DS. These recommendations are available at",
"      <a class=\"external\" href=\"file://pediatrics.aappublications.org/content/128/2/393.full.pdf+html\">",
"       pediatrics.aappublications.org/content/128/2/393.full.pdf+html",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      The following evaluations are recommended:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Plot growth on standard National Center for Health Statistics or World Health Organization growth charts; monitor for disturbances of growth associated with other disorders, such as hypothyroidism or celiac disease, and for excessive weight gain.",
"     </li>",
"     <li>",
"      Pediatric cardiology evaluation, including an echocardiogram, in the newborn period for congenital heart disease and continued clinical cardiac monitoring in adolescence and adulthood for mitral valve prolapse and aortic regurgitation.",
"     </li>",
"     <li>",
"      Newborn hearing screen and ongoing hearing screening throughout childhood, plus monitoring for otitis media, which is a common cause of hearing loss in children with DS.",
"     </li>",
"     <li>",
"      An ophthalmologic assessment before six months of age and then approximately annually to screen for ophthalmologic disorders.",
"     </li>",
"     <li>",
"      Thyroid function testing in the newborn period with newborn state screens, and repeated at 6 months of age, 12 months of age, and then yearly thereafter.",
"     </li>",
"     <li>",
"      Monitor for symptoms of celiac disease beginning at one year of age. Screening is recommended if signs or symptoms develop.",
"     </li>",
"     <li>",
"      A complete blood count and differential at birth to evaluate for myeloproliferative disorders and polycythemia; ongoing monitoring for signs of leukemia.",
"     </li>",
"     <li>",
"      Check hemoglobin level annually starting at one year of age to screen for iron-deficiency anemia.",
"     </li>",
"     <li>",
"      Neurologic evaluation for signs and symptoms consistent with spinal cord injury at each health supervision visit; symptomatic children should have an MRI to clarify the extent of spinal cord compression.",
"     </li>",
"     <li>",
"      Monitoring for symptoms related to sleep apnea at health supervision visits beginning at age one year; polysomnography is in all children with DS by four years of age.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Life expectancy in DS is shorter than that in the general population or in individuals with other causes of intellectual disability. However, survival has improved substantially in the past two to three decades.",
"     </li>",
"     <li>",
"      Internet resources for parents and patients include the following:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The Association for Children with Down Syndrome &mdash;",
"      <a class=\"external\" href=\"file://www.acds.org/\">",
"       www.acds.org",
"      </a>",
"     </li>",
"     <li>",
"      National Down Syndrome Congress &mdash;",
"      <a class=\"external\" href=\"file://www.ndsccenter.org/\">",
"       www.ndsccenter.org",
"      </a>",
"     </li>",
"     <li>",
"      National Down Syndrome Society &mdash;",
"      <a class=\"external\" href=\"file://www.ndss.org/\">",
"       www.ndss.org",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13224/abstract/1\">",
"      Bull MJ, Committee on Genetics. Health supervision for children with Down syndrome. Pediatrics 2011; 128:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13224/abstract/2\">",
"      Roizen NJ, Patterson D. Down's syndrome. Lancet 2003; 361:1281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13224/abstract/3\">",
"      Weijerman ME, de Winter JP. Clinical practice. The care of children with Down syndrome. Eur J Pediatr 2010; 169:1445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13224/abstract/4\">",
"      Luke A, Sutton M, Schoeller DA, Roizen NJ. Nutrient intake and obesity in prepubescent children with Down syndrome. J Am Diet Assoc 1996; 96:1262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13224/abstract/5\">",
"      Sep&uacute;lveda D, Allison DB, Gomez JE, et al. Low spinal and pelvic bone mineral density among individuals with Down syndrome. Am J Ment Retard 1995; 100:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13224/abstract/6\">",
"      Angelopoulou N, Souftas V, Sakadamis A, Mandroukas K. Bone mineral density in adults with Down's syndrome. Eur Radiol 1999; 9:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13224/abstract/7\">",
"      Fudge JC Jr, Li S, Jaggers J, et al. Congenital heart surgery outcomes in Down syndrome: analysis of a national clinical database. Pediatrics 2010; 126:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13224/abstract/8\">",
"      Posner EB, Colver AF. Thyroid dysfunction in Down's syndrome: relation to age and thyroid autoimmunity. Arch Dis Child 1999; 81:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13224/abstract/9\">",
"      Gibson PA, Newton RW, Selby K, et al. Longitudinal study of thyroid function in Down's syndrome in the first two decades. Arch Dis Child 2005; 90:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13224/abstract/10\">",
"      Van Vliet G. How often should we screen children with Down's syndrome for hypothyroidism? Arch Dis Child 2005; 90:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13224/abstract/11\">",
"      McGowan S, Jones J, Brown A, et al. Capillary TSH screening programme for Down's syndrome in Scotland, 1997-2009. Arch Dis Child 2011; 96:1113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13224/abstract/12\">",
"      Massey GV, Zipursky A, Chang MN, et al. A prospective study of the natural history of transient leukemia (TL) in neonates with Down syndrome (DS): Children's Oncology Group (COG) study POG-9481. Blood 2006; 107:4606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13224/abstract/13\">",
"      Hennequin M, Faulks D, Veyrune JL, Bourdiol P. Significance of oral health in persons with Down syndrome: a literature review. Dev Med Child Neurol 1999; 41:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13224/abstract/14\">",
"      Barr-Agholme M, Dahll&ouml;f G, Linder L, Mod&eacute;er T. Actinobacillus actinomycetemcomitans, Capnocytophaga and Porphyromonas gingivalis in subgingival plaque of adolescents with Down's syndrome. Oral Microbiol Immunol 1992; 7:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13224/abstract/15\">",
"      Kusters MA, Verstegen RH, Gemen EF, de Vries E. Intrinsic defect of the immune system in children with Down syndrome: a review. Clin Exp Immunol 2009; 156:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13224/abstract/16\">",
"      Atlantoaxial instability in Down syndrome: subject review. American Academy of Pediatrics Committee on Sports Medicine and Fitness. Pediatrics 1995; 96:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13224/abstract/17\">",
"      Pueschel SM, Herndon JH, Gelch MM, et al. Symptomatic atlantoaxial subluxation in persons with Down syndrome. J Pediatr Orthop 1984; 4:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13224/abstract/18\">",
"      American Academy of Pediatrics. Committee on Genetics. American Academy of Pediatrics: Health supervision for children with Down syndrome. Pediatrics 2001; 107:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13224/abstract/19\">",
"      Hsiang YH, Berkovitz GD, Bland GL, et al. Gonadal function in patients with Down syndrome. Am J Med Genet 1987; 27:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13224/abstract/20\">",
"      Bovicelli L, Orsini LF, Rizzo N, et al. Reproduction in Down syndrome. Obstet Gynecol 1982; 59:13S.",
"     </a>",
"    </li>",
"    <li>",
"     Issues of Sexualtiy in Down Syndrome. file://www.ds-health.com/issues.htm (Accessed on July 19, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13224/abstract/22\">",
"      Johannisson R, Gropp A, Winking H, et al. Down's syndrome in the male. Reproductive pathology and meiotic studies. Hum Genet 1983; 63:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13224/abstract/23\">",
"      Sheridan R, Llerena J Jr, Matkins S, et al. Fertility in a male with trisomy 21. J Med Genet 1989; 26:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13224/abstract/24\">",
"      Pradhan M, Dalal A, Khan F, Agrawal S. Fertility in men with Down syndrome: a case report. Fertil Steril 2006; 86:1765.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13224/abstract/25\">",
"      Yang Q, Rasmussen SA, Friedman JM. Mortality associated with Down's syndrome in the USA from 1983 to 1997: a population-based study. Lancet 2002; 359:1019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13224/abstract/26\">",
"      Strauss D, Eyman RK. Mortality of people with mental retardation in California with and without Down syndrome, 1986-1991. Am J Ment Retard 1996; 100:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13224/abstract/27\">",
"      Irving CA, Chaudhari MP. Cardiovascular abnormalities in Down's syndrome: spectrum, management and survival over 22 years. Arch Dis Child 2012; 97:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13224/abstract/28\">",
"      Kucik JE, Shin M, Siffel C, et al. Trends in survival among children with Down syndrome in 10 regions of the United States. Pediatrics 2013; 131:e27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13224/abstract/29\">",
"      Rasmussen SA, Wong LY, Correa A, et al. Survival in infants with Down syndrome, Metropolitan Atlanta, 1979-1998. J Pediatr 2006; 148:806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13224/abstract/30\">",
"      Rankin J, Tennant PW, Bythell M, Pearce MS. Predictors of survival in children born with Down syndrome: a registry-based study. Pediatrics 2012; 129:e1373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13224/abstract/31\">",
"      Glasson EJ, Sullivan SG, Hussain R, et al. The changing survival profile of people with Down's syndrome: implications for genetic counselling. Clin Genet 2002; 62:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13224/abstract/32\">",
"      Glasson EJ, Sullivan SG, Hussain R, et al. Comparative survival advantage of males with Down syndrome. Am J Hum Biol 2003; 15:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13224/abstract/33\">",
"      Wiseman FK, Alford KA, Tybulewicz VL, Fisher EM. Down syndrome--recent progress and future prospects. Hum Mol Genet 2009; 18:R75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13224/abstract/34\">",
"      Wetmore DZ, Garner CC. Emerging pharmacotherapies for neurodevelopmental disorders. J Dev Behav Pediatr 2010; 31:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13224/abstract/35\">",
"      Bianchi P, Ciani E, Guidi S, et al. Early pharmacotherapy restores neurogenesis and cognitive performance in the Ts65Dn mouse model for Down syndrome. J Neurosci 2010; 30:8769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13224/abstract/36\">",
"      Ani C, Grantham-McGregor S, Muller D. Nutritional supplementation in Down syndrome: theoretical considerations and current status. Dev Med Child Neurol 2000; 42:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13224/abstract/37\">",
"      Garcez ME, Peres W, Salvador M. Oxidative stress and hematologic and biochemical parameters in individuals with Down syndrome. Mayo Clin Proc 2005; 80:1607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13224/abstract/38\">",
"      Capone GT. Down syndrome: advances in molecular biology and the neurosciences. J Dev Behav Pediatr 2001; 22:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13224/abstract/39\">",
"      Miles MV, Patterson BJ, Chalfonte-Evans ML, et al. Coenzyme Q10 (ubiquinol-10) supplementation improves oxidative imbalance in children with trisomy 21. Pediatr Neurol 2007; 37:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13224/abstract/40\">",
"      Ellis JM, Tan HK, Gilbert RE, et al. Supplementation with antioxidants and folinic acid for children with Down's syndrome: randomised controlled trial. BMJ 2008; 336:594.",
"     </a>",
"    </li>",
"    <li>",
"     Babies with Down syndrome: A new parent's guide, 2nd ed, Stray-Gundersen K (Ed), Woodbine House, Bethesda 1995.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2938 Version 19.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-8C00B56BB2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_58_13224=[""].join("\n");
var outline_f12_58_13224=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H2085169\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GROWTH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Obesity prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CARDIAC DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      HEARING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      OPHTHALMOLOGIC DISORDERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      THYROID FUNCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CELIAC DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      HEMATOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      PERIODONTAL DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      ATLANTOAXIAL INSTABILITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      BEHAVIOR AND PSYCHIATRIC PROBLEMS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SLEEP APNEA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4399687\">",
"      FERTILITY AND REPRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2688753\">",
"      ALZHEIMER DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      LIFE EXPECTANCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2067895\">",
"      BASIC SCIENCE RESEARCH AND FUTURE TREATMENT OPTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      ALTERNATIVE TREATMENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      COUNSELING AND RESOURCES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2085169\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/60/29642?source=related_link\">",
"      Acute otitis media in children: Epidemiology, microbiology, clinical manifestations, and complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/18/26922?source=related_link\">",
"      Attention deficit hyperactivity disorder in children and adolescents: Clinical features and evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/14/22761?source=related_link\">",
"      Cataract in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/39/2682?source=related_link\">",
"      Clinical features and detection of congenital hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/15/26874?source=related_link\">",
"      Clinical features and diagnosis of Down syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/3/37946?source=related_link\">",
"      Clinical manifestations and diagnosis of celiac disease in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/0/23562?source=related_link\">",
"      Congenital cytogenetic abnormalities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/44/33482?source=related_link\">",
"      Congenital heart disease (CHD) in the newborn: Presentation and screening for critical CHD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/29/19928?source=related_link\">",
"      Developmental and behavioral screening tests in primary care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/8/34951?source=related_link\">",
"      Evaluation and management of strabismus in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/25/28057?source=related_link\">",
"      Evaluation of cognitive impairment and dementia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/19/44344?source=related_link\">",
"      Evaluation of hearing impairment in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/38/44649?source=related_link\">",
"      Evaluation of suspected obstructive sleep apnea in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/1/38936?source=related_link\">",
"      Management and outcome of isolated atrial septal defects in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/55/34680?source=related_link\">",
"      Management of isolated ventricular septal defects in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/17/40217?source=related_link\">",
"      Management of obstructive sleep apnea in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/42/33448?source=related_link\">",
"      Management of patent ductus arteriosus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/14/31976?source=related_link\">",
"      Measurement of growth in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/36/9801?source=related_link\">",
"      Mechanisms and predisposing factors for sleep related breathing disorders in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/6/36968?source=related_link\">",
"      Neonatal polycythemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/45/32471?source=related_link\">",
"      Overview of gingivitis and periodontitis in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/23/34165?source=related_link\">",
"      Overview of nystagmus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/27/22969?source=related_link\">",
"      Overview of prenatal screening and diagnosis of Down syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/7/28794?source=related_link\">",
"      Overview of the management of tetralogy of Fallot",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/58/4009?source=related_link\">",
"      Overview of the presentation and classification of acute lymphoblastic leukemia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?28/45/29394?source=related_link\">",
"      Patient information: Down syndrome (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?33/28/34242?source=related_link\">",
"      Patient information: Down syndrome (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/26/12713?source=related_link\">",
"      Primary care of the adult with intellectual disability (mental retardation)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/13/43225?source=related_link\">",
"      Screening tests in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/13/27865?source=related_link\">",
"      Screening the newborn for hearing loss",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/60/8137?source=related_link\">",
"      Systemic conditions associated with periodontal disease in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/4/33865?source=related_link\">",
"      Treatment of dementia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/59/24505?source=related_link\">",
"      Visual development and vision assessment in infants and children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_58_13225="Prevention of bicycle injuries in children";
var content_f12_58_13225=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Prevention of bicycle injuries in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/58/13225/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/58/13225/contributors\">",
"     Anne C Gill, DrPH, RN, MS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/58/13225/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/58/13225/contributors\">",
"     Jan E Drutz, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/58/13225/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/58/13225/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/58/13225/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 1, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bicycles were first marketed in the United States during the 1830s, but were too expensive for most people to buy. With the advent of the \"safety bicycle\" in the 1880s, bicycles became affordable, and bicycling became a national pastime. It is estimated that 44.3 million children and youth younger than 21 years ride bicycles in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13225/abstract/1\">",
"     1",
"    </a>",
"    ]. Bicycles result in more childhood injuries than any other consumer product except the automobile [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13225/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic review will describe the epidemiology of bicycle injuries, review strategies for prevention of bicycle injuries in children, and define the clinician's role in bicycle safety. General principles of injury prevention are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/31/11767?source=see_link\">",
"     \"Overview of pediatric injury prevention: Epidemiology; history; application\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term \"pedal cycle\" is defined by the International Classification of Diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13225/abstract/3\">",
"     3",
"    </a>",
"    ] as any road transport vehicle operated solely by pedals. A pedal cycle includes a bicycle, unicycle, or tricycle. Toys that a child straddles and propels with his or her feet are not pedal cycles and will not be discussed in this topic review.",
"   </p>",
"   <p>",
"    A pedal cyclist is any person riding on a pedal cycle or riding in an attachment to such a vehicle. Although pedal cycle is the common language used in injury surveillance and reporting, the word \"bicycle\" will be used in this report unless specified otherwise.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     SCOPE OF THE PROBLEM",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Epidemiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;According to the Centers for Disease Control and Prevention (CDC), in 2008, 276,020 children &le;19 years of age sustained injuries associated with bicycles [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13225/abstract/4\">",
"     4",
"    </a>",
"    ]. Children between the ages of 5 and 14 years are at the highest risk for bicycle injury [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13225/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Bicycle injuries in children typically are caused by falls or collision with a fixed or moving object. Serious injuries and fatalities are usually caused by collisions with motor vehicles [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13225/abstract/7,8\">",
"     7,8",
"    </a>",
"    ], and these typically occur within one mile of the bicyclist's home [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13225/abstract/9\">",
"     9",
"    </a>",
"    ]. Bicycle riding accounts for approximately 6 percent of fatal injuries and 5 percent of nonfatal injuries sustained during transportation to or from school transportation [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13225/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In 2008, there were 101 bicycle-associated deaths among children &le;15 years of age in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13225/abstract/11\">",
"     11",
"    </a>",
"    ]. Children between 10 and 15 years of age have the highest death rate [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13225/abstract/7,9,12-14\">",
"     7,9,12-14",
"    </a>",
"    ]. The majority of bicycle-related deaths (82 percent) and nonfatal injuries (71 percent) occur in boys [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13225/abstract/9\">",
"     9",
"    </a>",
"    ]. Fifty-three percent of all childhood bicycle-related deaths occur on secondary roads [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13225/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among children younger than 14 years of age, most bicycle fatalities (more than 80 percent) are associated with the bicyclist's behavior (eg, not following the rules of the road: riding against the flow of traffic, riding into the street without stopping, etc.) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13225/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Types of injuries",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data from the Kids' Inpatient Database (KID) indicate that an estimated 10,700 children were hospitalized for bicycle-related injuries in the United States in 2003 [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13225/abstract/15\">",
"     15",
"    </a>",
"    ]. Fractures and traumatic brain injury occurred in 53 and 34 percent of the cases, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13225/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Traumatic brain injury is the leading cause of death and long-term disability in bicycle crashes [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13225/abstract/8,16-19\">",
"     8,16-19",
"    </a>",
"    ]. An estimated 140,000 children are treated each year in emergency departments in the United States for traumatic brain injuries sustained while riding bicycles [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13225/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to head injuries, injuries to the musculoskeletal system and internal organs are important causes of bicycle-related morbidity [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13225/abstract/5\">",
"     5",
"    </a>",
"    ]. In 1997, handlebar injuries to the abdominal or pelvic organs led to the hospitalization of an estimated 1147 subjects &le;19 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13225/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Young children who ride in bicycle-mounted seats are also at risk for injury [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13225/abstract/6\">",
"     6",
"    </a>",
"    ]. Feet, legs, or clothing can get caught in the spokes of the bicycle wheel [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13225/abstract/22-24\">",
"     22-24",
"    </a>",
"    ]. In addition, the added weight may make it more difficult for parents to control the bicycle or stop in time [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13225/abstract/25\">",
"     25",
"    </a>",
"    ]. When falls occur, children in bicycle-mounted seats are exposed to adult-level forces of speed [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13225/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Bike trailers are hitched and towed behind the parent and should not be used by infants. Likewise, the \"trail-a-bike,\" which converts an adult bicycle into a three-wheel tandem, should not be used by children younger than three years of age. Both of these products reduce the impact of forces from collisions related to height. However, injury data have not been studied, and these items have other safety issues related to product failure [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13225/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Socioeconomic impact",
"    </span>",
"    &nbsp;&mdash;&nbsp;The annual cost of traffic-related bicyclist death and injury for children &le;14 years is $2.2 billion [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13225/abstract/9,28\">",
"     9,28",
"    </a>",
"    ]. In 2003, bicycle-related injuries in children resulted in an estimated $200 million in total hospital costs [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13225/abstract/15\">",
"     15",
"    </a>",
"    ]. In the same year, handlebar injuries to the abdominal or pelvic organs among children &le;19 years of age resulted in an estimated total hospital cost of $10 million [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13225/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Bicycle helmets, discussed below, are the single most effective measure for the prevention of significant bicycle injury. Among injury prevention interventions, child bicycle helmets have one of the highest cost-benefit ratios [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13225/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. Assuming an 85 percent use rate, the average bicycle helmet can save an estimated $440 over 5 years [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13225/abstract/29\">",
"     29",
"    </a>",
"    ]. Even with the most conservative estimates, universal bicycle helmet use would have prevented 56,000 bicycle-related head injuries and yielded $1.3 billion in savings from health costs during 1997 [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13225/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to age and sex, other factors associated with bicycle injury have been described, primarily in case-control studies [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13225/abstract/9,32-36\">",
"     9,32-36",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nondaylight riding: children ages 14 and under are nearly four times more likely to be injured riding at dawn, dusk, or night than during the daytime [",
"      <a class=\"abstract\" href=\"UTD.htm?12/58/13225/abstract/9\">",
"       9",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Exposure time: in one study, bicycle injury was more common among children who rode their bicycles &gt;3 hours per week than among those who rode &lt;1 hour (odds ratio 2.2) [",
"      <a class=\"abstract\" href=\"UTD.htm?12/58/13225/abstract/32\">",
"       32",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Riding on the sidewalk: perhaps related to difficulties in negotiating uneven surfaces [",
"      <a class=\"abstract\" href=\"UTD.htm?12/58/13225/abstract/32\">",
"       32",
"      </a>",
"      ] or lack of proficiency [",
"      <a class=\"abstract\" href=\"UTD.htm?12/58/13225/abstract/34\">",
"       34",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Using the bicycle for play, rather than transportation, has been identified as a risk factor in some [",
"      <a class=\"abstract\" href=\"UTD.htm?12/58/13225/abstract/32,34\">",
"       32,34",
"      </a>",
"      ], but not all [",
"      <a class=\"abstract\" href=\"UTD.htm?12/58/13225/abstract/33\">",
"       33",
"      </a>",
"      ], case-control studies",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     PREVENTION OF BICYCLE-RELATED INJURIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with most other injury prevention programs, research continues to support a combination or layering of multiple interventions as the best approach in increasing bicycle safety [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13225/abstract/37-40\">",
"     37-40",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/31/11767?source=see_link&amp;anchor=H4#H4\">",
"     \"Overview of pediatric injury prevention: Epidemiology; history; application\", section on 'Principles of injury prevention and control'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Bicycle helmet use",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because head injuries account for the majority of bicycle-related deaths and hospital admissions, wearing a bicycle helmet is the first rule of bicycle safety. Multiple studies have shown that the use of a bicycle helmet reduces the risk of brain injury [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13225/abstract/41-49\">",
"     41-49",
"    </a>",
"    ]. A systematic review of five case-control studies [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13225/abstract/42-45,48\">",
"     42-45,48",
"    </a>",
"    ] found that helmets provide a 63 to 88 percent reduction in the risk of head, brain, and severe brain injuries for bicyclists of all ages [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13225/abstract/47\">",
"     47",
"    </a>",
"    ]. Helmets provide similar protection for crashes involving motor vehicles and other causes (approximately 70 percent). In addition, bicycle helmet use reduced injuries to the upper and mid-face by 65 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13225/abstract/47\">",
"     47",
"    </a>",
"    ]. One of the case-control studies included in the systematic review was limited to children &lt;15 years of age; in this study, wearing a helmet reduced the risk of head injury by 63 percent, and of loss of consciousness by 86 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13225/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Bicycle helmet use has increased since the 1980s, when fewer than 5 percent of children were observed to wear bicycle helmets [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13225/abstract/37,50\">",
"     37,50",
"    </a>",
"    ]. In 1994, helmet ownership among children 5 to 14 years of age was estimated at 25 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13225/abstract/40\">",
"     40",
"    </a>",
"    ], and a state-by-state survey conducted in 1995 revealed a range of usage from 9 percent in Mississippi to 63 percent in Oregon [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13225/abstract/51\">",
"     51",
"    </a>",
"    ]. In the fall of 2003, the National Safe Kids Campaign performed an observational survey of helmet use at 549 sites in 46 states and the District of Columbia [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13225/abstract/52\">",
"     52",
"    </a>",
"    ]. The following results were reported:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Forty-one percent of children were observed to wear helmets while participating in wheeled sports (bicycling, in-line skating, scooters, skateboards)",
"     </li>",
"     <li>",
"      More than one-third of the children wore the helmets incorrectly (eg, tilted or with the chin strap loose or unfastened)",
"     </li>",
"     <li>",
"      Helmet use was greatest on bicycle paths and in parks or playgrounds (50 and 42 percent, respectively), and lower at schools and on residential streets (38 and 33 percent, respectively)",
"     </li>",
"     <li>",
"      Helmet use was higher at sites where there was adult supervision (47 versus 37 percent), particularly when adults who were riding with children also wore helmets (67 versus 50 percent who were accompanied by adults not wearing helmets)",
"     </li>",
"     <li>",
"      Helmet use was more common among children in locations with statewide laws requiring helmet use (45 versus 39 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The increase in helmet use has been attributed to an increase in state bicycle helmet laws [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13225/abstract/53-56\">",
"     53-56",
"    </a>",
"    ] and strict enforcement of the legislation [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13225/abstract/57\">",
"     57",
"    </a>",
"    ]. Survey data indicate bicycle helmet use is also influenced by parental rules and the age and attitudes of the children [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13225/abstract/58,59\">",
"     58,59",
"    </a>",
"    ]. In a telephone survey, injury prevention counseling was associated with an increase in \"always wearing a helmet\" in 5- to 14-year-olds (58 versus 44 percent in those who did not receive counseling) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13225/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Even if they have a helmet, many children do not wear it every time they ride [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13225/abstract/61\">",
"     61",
"    </a>",
"    ]. Parents and children provide different reasons for lack of helmet use. Reasons provided by parents include lack of knowledge [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13225/abstract/62,63\">",
"     62,63",
"    </a>",
"    ] and cost of the helmet [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13225/abstract/37,64\">",
"     37,64",
"    </a>",
"    ]. Reasons provided by children include that they don't own a helmet [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13225/abstract/35\">",
"     35",
"    </a>",
"    ], helmets are uncool and not used by their friends [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13225/abstract/20\">",
"     20",
"    </a>",
"    ], helmets are uncomfortable [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13225/abstract/35,65\">",
"     35,65",
"    </a>",
"    ] or inconvenient [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13225/abstract/58\">",
"     58",
"    </a>",
"    ], and that helmets are not needed (eg, for casual riding, in contrast to sport or race bicycling) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13225/abstract/40,66\">",
"     40,66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although it is increasing, helmet use among teenagers is particularly low. In the 1997 Youth Risk Behavior Survey, 75 percent of students reported riding a bicycle in the previous 12 months, but only 3.8 percent reported that they always wore a helmet when bicycling [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13225/abstract/67\">",
"     67",
"    </a>",
"    ]. The prevalence of never or rarely wearing a helmet declined from 96.2 to 84.7 percent between 1991 and 2001, but then did not change significantly between 2001 and 2011 (84.7 and 87.5 percent), an overall decline of 8.7 percentage points between 1991 and 2011 [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13225/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In another survey, only 3 percent of 14- to 15-year-olds reported helmet use, whereas 80 percent of 12- to 13-year-olds reported wearing helmets when they were younger [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13225/abstract/58\">",
"     58",
"    </a>",
"    ]. Because of these dismal findings, the American Association of Pediatrics (AAP) and other groups (eg, the National Safe Kids Campaign and Healthy People 2020) have called for increased efforts to promote bicycle helmet usage among adolescents [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13225/abstract/69,70\">",
"     69,70",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Helmet specifications",
"    </span>",
"    &nbsp;&mdash;&nbsp;In March 1999, the United States Consumer Product Safety Commission (CPSC) established federal safety standards for bicycle helmets sold in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13225/abstract/71\">",
"     71",
"    </a>",
"    ]. These standards replace the voluntary standards established by the American National Standards Institute (ANSI), the Snell Memorial Foundation, and the American Society for Testing and Materials (ASTM). Helmets that meet the CPSC standards have a CPSC sticker on the inside liner. Improvements in helmet design have led to the manufacture of rounder, more compact bike helmets with more foam and fewer air vents [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13225/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Older helmets certified by the ASTM",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the Snell Memorial Foundation may continue to be used, but helmets certified only by the ANSI should be discarded (they were not tested at the current standard) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13225/abstract/69\">",
"     69",
"    </a>",
"    ]. Multisport helmets, designed to be worn for several wheeled recreational activities including bicycling, must be certified to meet the CPSC standard for bicycle helmets.",
"   </p>",
"   <p>",
"    In addition, helmets that have been in a crash in which the head has hit a hard surface or in which a fall has resulted in marks on the shell should be discarded immediately [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13225/abstract/69\">",
"     69",
"    </a>",
"    ]. Helmets older than five years should be replaced due to possible product deterioration [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13225/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Helmet fit",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is important that the helmet fit correctly and be worn in the proper position. In a study of helmet fit and risk of head injury, children who wore poorly fitting helmets had nearly two times the risk of head injury in a crash compared with children who wore properly fitted helmets [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13225/abstract/73\">",
"     73",
"    </a>",
"    ]. In addition, children who wore the helmet tipped posteriorly had a 52 percent increase in the risk of head injury during a crash compared with children who wore the helmet centered on their heads [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13225/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Children and parents may benefit from review of proper helmet fit and positioning. In one study of children aged 4 to 18 years presenting for a health maintenance visit, 96 percent of children and adolescents wore helmets that were either in unsatisfactory condition or did not fit properly [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13225/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    To help parents properly fit their children's helmets, the Bicycle Helmet Safety Institute developed the following guidelines, which can be downloaded from their Web site at",
"    <a class=\"external\" href=\"file://www.bhsi.org/fit.htm\">",
"     www.bhsi.org/fit.htm",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The helmet should rest just above the eyebrows and not slide around on the head (",
"      <a class=\"graphic graphic_figure graphicRef80155 \" href=\"UTD.htm?34/23/35198\">",
"       figure 1",
"      </a>",
"      ). Use the foam pads to raise or lower the helmet or pad the side space if necessary.",
"     </li>",
"     <li>",
"      The straps of the helmet should be adjusted to form a Y just under the ear of the child.",
"     </li>",
"     <li>",
"      The chin strap should be snug enough to pull down on the helmet when the child opens the mouth wide.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Bicycle safety programs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bicycle safety programs include legislation, awareness (education), and giveaway programs to increase the use of bicycle helmets. Of the three, legislation has achieved the greatest increase in bicycle helmet use. Multiple studies have demonstrated not only an increase in the use of bicycle helmets [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13225/abstract/54,55,75\">",
"     54,55,75",
"    </a>",
"    ], but also a decrease in serious head injuries [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13225/abstract/56,76-78\">",
"     56,76-78",
"    </a>",
"    ] following the passage of bicycle helmet laws.",
"   </p>",
"   <p>",
"    Awareness or education programs in the school",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    community [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13225/abstract/79-82\">",
"     79-82",
"    </a>",
"    ] and by physicians [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13225/abstract/64,83\">",
"     64,83",
"    </a>",
"    ] have also led to increases in the use of bicycle helmets. A systematic review of nonlegislative interventions for the promotion of helmet wearing by children found an increase in observed helmet wearing after educational programs, particularly those that were community based and provided free helmets [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13225/abstract/82\">",
"     82",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Giveaway programs, although initially successful, have not been found to have a sustained effect in increasing the use of bicycle helmets [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13225/abstract/57,84\">",
"     57,84",
"    </a>",
"    ]. In one giveaway program, researchers recommended a co-pay as a way to increase the number of helmets available to give to low-income families [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13225/abstract/85\">",
"     85",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Bicycle paths",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because the majority of serious bicycle injuries and fatalities are usually caused by collisions with motor vehicles [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13225/abstract/7,8\">",
"     7,8",
"    </a>",
"    ], it makes sense to try to separate young recreational cyclists from motor vehicle traffic [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13225/abstract/86,87\">",
"     86,87",
"    </a>",
"    ]. Researchers in the Netherlands and Germany attribute a dramatic reduction in both pedestrian and bicycle injuries to improvements in infrastructure, which included bike paths and improved street markings [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13225/abstract/88\">",
"     88",
"    </a>",
"    ]. Although the benefits of bicycle lanes and bicycle paths have yet to be proven conclusively, evidence suggests that an increase in dedicated bike lanes increases the number of cyclists, which in turn reduces the number of bicycle injuries due to greater visibility and awareness [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13225/abstract/89-92\">",
"     89-92",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     CLINICIAN'S ROLE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Health-care providers play an important role in increasing the use of bicycle helmets [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13225/abstract/50,69,93\">",
"     50,69,93",
"    </a>",
"    ]. However, only 33 to 44 percent of parents [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13225/abstract/40,62\">",
"     40,62",
"    </a>",
"    ] and 22 percent of children [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13225/abstract/94\">",
"     94",
"    </a>",
"    ] surveyed report receiving bicycle safety counseling from their child's health-care provider. Pediatric health-care providers should encourage parents and caregivers to require children to wear bicycle helmets as soon as they begin riding, and to model wearing a helmet themselves [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13225/abstract/69,95\">",
"     69,95",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, as advocates for children, physicians can encourage state and local legislation requiring bicycle helmet use for all children.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Anticipatory guidance",
"    </span>",
"    &nbsp;&mdash;&nbsp;The anticipatory guidance for prevention of bicycle injuries varies according to the age of the child.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Children &lt;1 year",
"    </span>",
"    &nbsp;&mdash;&nbsp;Parents with infants should be cautioned against the use of bicycle-mounted child seats [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13225/abstract/96\">",
"     96",
"    </a>",
"    ]. The American Academy of Pediatrics (AAP) recommends that no child younger than one year of age ride as a passenger on a bicycle restraining seat [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13225/abstract/69\">",
"     69",
"    </a>",
"    ]. In addition, it is unsafe to use infant carriers, such as backpacks and front packs, to transport infants on bicycles [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13225/abstract/97\">",
"     97",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Children 1-5 years",
"    </span>",
"    &nbsp;&mdash;&nbsp;Parents should be counseled about injury prevention if they choose to use bicycle-mounted carriers. The carrier should be securely mounted and should have a spoke guard to protect the child's hands and feet; the seat should have a high back and a shoulder harness and lap belt that would adequately support a sleeping child; the child should never be left alone in the bicycle carrier [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13225/abstract/97\">",
"     97",
"    </a>",
"    ]. Mounted-carrier riding becomes less safe as the child approaches the age of four years and his or her weight makes the bicycle unstable and difficult to handle [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13225/abstract/97\">",
"     97",
"    </a>",
"    ]. Bicycle-towed trailers are a safer alternative to bicycle-mounted child seats [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13225/abstract/22\">",
"     22",
"    </a>",
"    ]. The trailer provides greater stability, is out of reach of the spokes, and is lower to the ground in the event of a fall. All child passengers should wear an appropriately sized and properly fastened helmet (",
"    <a class=\"graphic graphic_figure graphicRef80155 \" href=\"UTD.htm?34/23/35198\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13225/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A child should not be allowed to ride a tricycle or bicycle until he or she is developmentally ready [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13225/abstract/98\">",
"     98",
"    </a>",
"    ]. In general, children younger than three years do not have the cognitive or physical ability to both pedal and steer. According to the United States Consumer Product Safety Commission&rsquo;s (CPSC) Age Determination Guidelines, a tricycle should have wheels that are 12 to 13 inches in diameter [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13225/abstract/99\">",
"     99",
"    </a>",
"    ]. Three-year-old children may be able to use a small bicycle with training wheels, but because children of this age cannot yet use hand brakes, the bicycle should have foot brakes [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13225/abstract/99\">",
"     99",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Training wheels can facilitate the transition from tricycle to bicycle.",
"   </p>",
"   <p>",
"    The first bicycle should be of an appropriate size for the child. Parents should be discouraged from buying a \"bigger bicycle\" with the hopes a child will grow into it. To fit properly, a child should be able to sit on the seat and put the balls of both feet on the ground while holding the handlebars. To prevent straddle injuries, the child should have a one-inch clearance between the bar and the crotch when he or she straddles the bicycle and has both feet on the ground [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13225/abstract/100\">",
"     100",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/53/35669?source=see_link\">",
"     \"Straddle injuries\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    By five years of age, most children have the balance and coordination to ride bicycles with training wheels and foot brakes [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13225/abstract/99\">",
"     99",
"    </a>",
"    ]. However, they do not understand the risks of riding in areas with cars and should be taught to ride only in areas away from motorists (eg, parks or playgrounds) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13225/abstract/101\">",
"     101",
"    </a>",
"    ]. Basic bicycle skills include learning how to use the brakes to stop, and how to look left, right, and left again. Children should also practice the quick shoulder check by glancing behind while proceeding forward in a straight line. Once the basics are mastered, parents should instruct young children to ride on the sidewalk, avoid the street, and only to ride when accompanied by an adult.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Children 6-12 years",
"    </span>",
"    &nbsp;&mdash;&nbsp;By the age of six, most children are able to ride a bicycle without training wheels and have developed some understanding of the consequences of riding in areas shared by cars and pedestrians [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13225/abstract/99\">",
"     99",
"    </a>",
"    ]. Foot brakes on bicycles should be used until the child has developed the motor coordination to use hand brakes (usually by six years of age) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13225/abstract/99\">",
"     99",
"    </a>",
"    ]. As for younger children, the bicycle should be of an appropriate size for the child. To fit properly, a child should be able to sit on the seat and put the balls of both feet on the ground while holding the handlebars. The purchase of bicycle that the child can \"grow into\" should be discouraged.",
"    <a class=\"external\" href=\"file://patiented.aap.org/categoryBrowse.aspx?catID=27\">",
"     The Injury Prevention Program",
"    </a>",
"    (TIPP) of the AAP provides information to help parents teach young children bicycle safety.",
"   </p>",
"   <p>",
"    School-age children have the motor skills to become accomplished bike riders. However, children in this age group may engage in high-risk behavior and should be reminded to obey all traffic laws. The AAP offers the following bicycle safety recommendations for children in this age [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13225/abstract/102\">",
"     102",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Learn the rules of the road",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Ride with traffic",
"     </li>",
"     <li>",
"      Stop and look both ways before entering the street",
"     </li>",
"     <li>",
"      Stop at all intersections, marked and unmarked",
"     </li>",
"     <li>",
"      Before turning, use hand signals and look all ways",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Ride in single file and use bicycle paths whenever possible",
"     </li>",
"     <li>",
"      Avoid all trick and double riding (children should never ride on the handlebars or the crossbar [",
"      <a class=\"abstract\" href=\"UTD.htm?12/58/13225/abstract/22\">",
"       22",
"      </a>",
"      ])",
"     </li>",
"     <li>",
"      Do not ride at dusk or after dark",
"     </li>",
"     <li>",
"      Do not wear loose-fitting clothing. Wear shoes and tie the laces when riding.",
"     </li>",
"     <li>",
"      Do not wear earphones while riding",
"     </li>",
"     <li>",
"      Place objects in a backpack or a basket",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Adolescents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adolescents, who are at increased risk of bicycle injury and death, should be encouraged to wear bicycle helmets every time they ride. In addition, they should follow the bicycle safety recommendations listed above.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     RESOURCES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following Web resources may be helpful to pediatric health-care providers in counseling their patients and patients' families about bicycle safety:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"external\" href=\"file://www.healthychildren.org/English/safety-prevention/at-play/Pages/Bicycle-Helmets-What-Every-Parent-Should-Know.aspx?nfstatus=401&amp;nftoken=00000000-0000-0000-0000-000000000000&amp;nfstatusdescription=ERROR%3a+No+local+token&amp;nfstatus=401&amp;nftoken=00000000-0000-0000-0000-000000000000&amp;nfstatusdescription=ERROR%3a+No+local+token\">",
"       American Academy of Pediatrics: Healthy Children: Bicycle Helmets: What every parent should know",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"external\" href=\"file://www.healthychildren.org/English/safety-prevention/at-play/pages/Bicycle-Safety-Myths-And-Facts.aspx\">",
"       American Academy of Pediatrics: Bicycle Safety: Myths and Facts",
"      </a>",
"      <a class=\"external\" href=\"file://www.aap.org/family/tbikmyth.htm\">",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"external\" href=\"file://www.safekids.org/safety-basics/safety-resources-by-risk-area/bicycling-and-skating/bicycling-and-skating-safety.html\">",
"       National Safe Kids Campaign: Bicycling and Skating Tips",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"external\" href=\"file://www.bhsi.org/\">",
"       Bicycle Helmet Safety Institute",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"external\" href=\"file://www.bicyclinginfo.org/\">",
"       Pedestrian and Bicycle Information Center",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"external\" href=\"file://www.bicyclinginfo.org/network/\">",
"       National Bicycle Safety Network",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?13/44/14020?source=see_link\">",
"       \"Patient information: Head injury in children and adolescents (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children between the ages of 5 and 14 years are at the highest risk for bicycle injury [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13225/abstract/103\">",
"     103",
"    </a>",
"    ]. Head injuries account for the majority of bicycle-related deaths and hospital admissions. Bicycle helmets provide a 63 to 88 percent reduction in the risk of head, brain, and severe brain injuries for bicyclists of all ages [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13225/abstract/47\">",
"     47",
"    </a>",
"    ]. Thus, helmet use should be encouraged for bicycle riders and passengers of all ages, on every occasion that they ride a bicycle.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Only bicycle helmets that meet United States Consumer Product Safety Commission (CPSC) standards should be used; helmets that have been involved in a crash should be discarded.",
"     </li>",
"     <li>",
"      Bicycle helmets should fit properly and be worn in the proper position (",
"      <a class=\"graphic graphic_figure graphicRef80155 \" href=\"UTD.htm?34/23/35198\">",
"       figure 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Children younger than one year should not ride in bicycle-mounted carriers or trailers.",
"     </li>",
"     <li>",
"      When used, mounted carriers should be securely mounted and should have a spoke guard and seats with a high back, shoulder harness, and lap belt [",
"      <a class=\"abstract\" href=\"UTD.htm?12/58/13225/abstract/97\">",
"       97",
"      </a>",
"      ]. The use of mounted carriers should be discouraged as the child approaches four years of age since the weight of the child makes the bicycle unstable and difficult to handle.",
"     </li>",
"     <li>",
"      For child passengers, bicycle trailers are a safer alternative to bicycle-mounted carriers. Children who ride in bicycle trailers should wear a helmet.",
"     </li>",
"     <li>",
"      Children younger than three years do not have the developmental skills necessary to ride a tricycle.",
"     </li>",
"     <li>",
"      Children aged four to five usually can ride a bicycle with training wheels and foot-operated brakes; they should not ride in traffic and must be supervised at all times.",
"     </li>",
"     <li>",
"      Children aged six and older usually can ride a bicycle without training wheels and operate hand brakes; they begin to develop the skills necessary to ride in areas with pedestrians and traffic; children should not be permitted to ride in traffic until they have demonstrated that they can control the bicycle, understand and follow the rules of the road, and exercise good judgment. The age of attainment of these skills is different for different children.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13225/abstract/1\">",
"      Rodgers GB. Bicycle and bicycle helmet use patterns in the United States in 1998. J Safety Res 2000; 31:149.",
"     </a>",
"    </li>",
"    <li>",
"     US Consumer Product Safety Commission. National Electronic Injury Surveillance System (NEISS). 1999.",
"    </li>",
"    <li>",
"     American Medical Association. Physician ICD-9-Cm 2004: International Classification of Diseases, Clinical Modification 2003.",
"    </li>",
"    <li>",
"     CDC 2010. Web-Based Injury Statistics Query and Reporting System (WISQARS) [Online]. Centers for Disease Control and Prevention, National Center for Injury Prevention and Control and NCHS Vital Statistics System. Available at: www.cdc.gov/ncipc/wisqars (Accessed on May 19, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13225/abstract/5\">",
"      Mehan TJ, Gardner R, Smith GA, McKenzie LB. Bicycle-related injuries among children and adolescents in the United States. Clin Pediatr (Phila) 2009; 48:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13225/abstract/6\">",
"      Powell EC, Tanz RR. Cycling injuries treated in emergency departments: need for bicycle helmets among preschoolers. Arch Pediatr Adolesc Med 2000; 154:1096.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13225/abstract/7\">",
"      Acton CH, Thomas S, Nixon JW, et al. Children and bicycles: what is really happening? Studies of fatal and non-fatal bicycle injury. Inj Prev 1995; 1:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13225/abstract/8\">",
"      Puranik S, Long J, Coffman S. Profile of pediatric bicycle injuries. South Med J 1998; 91:1033.",
"     </a>",
"    </li>",
"    <li>",
"     National Safe Kids Campaign (NSKC). Bicycle Injury Fact Sheet. NSKC, Washington, DC, 2004.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13225/abstract/10\">",
"      American Academy of Pediatrics Committee on Injury, Violence, and Poison Prevention, American Academy of Pediatrics Council on School Health, Agran PF. School transportation safety. Pediatrics 2007; 120:213.",
"     </a>",
"    </li>",
"    <li>",
"     Traffic Safety Facts: 2008 Data. National Hightway Traffic and Safety Administration's National Center for Statistics and Analysis. Available at: www-nrd.nhtsa.dot.gov/pubs/811156.pdf (Accessed on May 24, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13225/abstract/12\">",
"      Weiss BD. Prevention of bicycle-related head injuries. Am J Prev Med 1986; 2:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13225/abstract/13\">",
"      Kraus JF, Fife D, Conroy C. Incidence, severity, and outcomes of brain injuries involving bicycles. Am J Public Health 1987; 77:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13225/abstract/14\">",
"      Agran PF, Winn D, Anderson C, et al. Rates of pediatric and adolescent injuries by year of age. Pediatrics 2001; 108:E45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13225/abstract/15\">",
"      Shah S, Sinclair SA, Smith GA, Xiang H. Pediatric hospitalizations for bicycle-related injuries. Inj Prev 2007; 13:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13225/abstract/16\">",
"      Li G, Baker SP, Fowler C, DiScala C. Factors related to the presence of head injury in bicycle-related pediatric trauma patients. J Trauma 1995; 38:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13225/abstract/17\">",
"      Nakayama DK, Gardner MJ, Rogers KD. Disability from bicycle-related injuries in children. J Trauma 1990; 30:1390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13225/abstract/18\">",
"      Sosin DM, Sacks JJ, Webb KW. Pediatric head injuries and deaths from bicycling in the United States. Pediatrics 1996; 98:868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13225/abstract/19\">",
"      Sleet DA, Ballesteros MF, Borse NN. A review of unintentional injuries in adolescents. Annu Rev Public Health 2010; 31:195.",
"     </a>",
"    </li>",
"    <li>",
"     National Center for Injury Prevention and Control. Injury Fact Book 2001-2002, Centers for Disease Control and Prevention, Atlanta, GA 2001.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13225/abstract/21\">",
"      Winston FK, Weiss HB, Nance ML, et al. Estimates of the incidence and costs associated with handlebar-related injuries in children. Arch Pediatr Adolesc Med 2002; 156:922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13225/abstract/22\">",
"      Powell EC, Tanz RR. Tykes and bikes: injuries associated with bicycle-towed child trailers and bicycle-mounted child seats. Arch Pediatr Adolesc Med 2000; 154:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13225/abstract/23\">",
"      Griffiths DM, MacKellar A. Bicycle-spoke and \"doubling\" injuries. Med J Aust 1988; 149:618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13225/abstract/24\">",
"      Segers MJ, Wink D, Clevers GJ. Bicycle-spoke injuries: a prospective study. Injury 1997; 28:267.",
"     </a>",
"    </li>",
"    <li>",
"     Wilson MH, Levin-Goodman R. Injury prevention and control. In: Oski's Pediatrics. Principles and Practice, 4th, McMillan JA, Feigin RD, DeAngelis C, Jones MD (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. p.134.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13225/abstract/26\">",
"      Tanz RR, Christoffel KK. Tykes on bikes: injuries associated with bicycle-mounted child seats. Pediatr Emerg Care 1991; 7:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13225/abstract/27\">",
"      Murray J, Ryan-Krause P. Bicycle attachments for children: bicycle seats, trail-a-bikes, and trailers. J Pediatr Health Care 2009; 23:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13225/abstract/28\">",
"      Sosin DM, Sniezek JE, Thurman DJ. Incidence of mild and moderate brain injury in the United States, 1991. Brain Inj 1996; 10:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13225/abstract/29\">",
"      Miller TR, Levy DT. Cost-outcome analysis in injury prevention and control: eighty-four recent estimates for the United States. Med Care 2000; 38:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13225/abstract/30\">",
"      Ginsberg GM, Silverberg DS. A cost-benefit analysis of legislation for bicycle safety helmets in Israel. Am J Public Health 1994; 84:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13225/abstract/31\">",
"      Schulman J, Sacks J, Provenzano G. State level estimates of the incidence and economic burden of head injuries stemming from non-universal use of bicycle helmets. Inj Prev 2002; 8:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13225/abstract/32\">",
"      Carlin JB, Taylor P, Nolan T. A case-control study of child bicycle injuries: relationship of risk to exposure. Accid Anal Prev 1995; 27:839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13225/abstract/33\">",
"      Agran PF, Winn DG. The bicycle: a developmental toy versus a vehicle. Pediatrics 1993; 91:752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13225/abstract/34\">",
"      Senturia YD, Morehead T, LeBailly S, et al. Bicycle-riding circumstances and injuries in school-aged children. A case-control study. Arch Pediatr Adolesc Med 1997; 151:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13225/abstract/35\">",
"      Finnoff JT, Laskowski ER, Altman KL, Diehl NN. Barriers to bicycle helmet use. Pediatrics 2001; 108:E4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13225/abstract/36\">",
"      Hu X, Wesson DE, Chipman ML, Parkin PC. Bicycling exposure and severe injuries in school-age children. A population-based study. Arch Pediatr Adolesc Med 1995; 149:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13225/abstract/37\">",
"      Bergman AB, Rivara FP, Richards DD, Rogers LW. The Seattle children's bicycle helmet campaign. Am J Dis Child 1990; 144:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13225/abstract/38\">",
"      Gielen AC, Sleet D. Application of behavior-change theories and methods to injury prevention. Epidemiol Rev 2003; 25:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13225/abstract/39\">",
"      Dowswell T, Towner EM, Simpson G, Jarvis SN. Preventing childhood unintentional injuries--what works? A literature review. Inj Prev 1996; 2:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13225/abstract/40\">",
"      Sacks JJ, Kresnow M, Houston B, Russell J. Bicycle helmet use among American children, 1994. Inj Prev 1996; 2:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13225/abstract/41\">",
"      Attewell RG, Glase K, McFadden M. Bicycle helmet efficacy: a meta-analysis. Accid Anal Prev 2001; 33:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13225/abstract/42\">",
"      Maimaris C, Summers CL, Browning C, Palmer CR. Injury patterns in cyclists attending an accident and emergency department: a comparison of helmet wearers and non-wearers. BMJ 1994; 308:1537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13225/abstract/43\">",
"      Thompson RS, Rivara FP, Thompson DC. A case-control study of the effectiveness of bicycle safety helmets. N Engl J Med 1989; 320:1361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13225/abstract/44\">",
"      Thompson DC, Rivara FP, Thompson RS. Effectiveness of bicycle safety helmets in preventing head injuries. A case-control study. JAMA 1996; 276:1968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13225/abstract/45\">",
"      Thomas S, Acton C, Nixon J, et al. Effectiveness of bicycle helmets in preventing head injury in children: case-control study. BMJ 1994; 308:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13225/abstract/46\">",
"      Spaite DW, Murphy M, Criss EA, et al. A prospective analysis of injury severity among helmeted and nonhelmeted bicyclists involved in collisions with motor vehicles. J Trauma 1991; 31:1510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13225/abstract/47\">",
"      Thompson DC, Rivara FP, Thompson R. Helmets for preventing head and facial injuries in bicyclists. Cochrane Database Syst Rev 2000; :CD001855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13225/abstract/48\">",
"      McDermott FT, Lane JC, Brazenor GA, Debney EA. The effectiveness of bicyclist helmets: a study of 1710 casualties. J Trauma 1993; 34:834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13225/abstract/49\">",
"      Persaud N, Coleman E, Zwolakowski D, et al. Nonuse of bicycle helmets and risk of fatal head injury: a proportional mortality, case-control study. CMAJ 2012; 184:E921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13225/abstract/50\">",
"      Weiss BD. Bicycle helmet use by children. Pediatrics 1986; 77:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13225/abstract/51\">",
"      Bland SD. Injury prevention behaviors: A report card for the nation, 1995. Prev Med 1999; 29:195.",
"     </a>",
"    </li>",
"    <li>",
"     Cody BE, Wuraishi AY, Mickalide AD. Headed for injury: An observational survey of helmet use among children ages 5 to 14 participating in wheeled sports. National Safe Kids Campaign, Washington, DC, May 2004.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13225/abstract/53\">",
"      Schieber RA, Kresnow MJ, Sacks JJ, et al. Effect of a state law on reported bicycle helmet ownership and use. Arch Pediatr Adolesc Med 1996; 150:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13225/abstract/54\">",
"      Ni H, Sacks JJ, Curtis L, et al. Evaluation of a statewide bicycle helmet law via multiple measures of helmet use. Arch Pediatr Adolesc Med 1997; 151:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13225/abstract/55\">",
"      Rodgers GB. Effects of state helmet laws on bicycle helmet use by children and adolescents. Inj Prev 2002; 8:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13225/abstract/56\">",
"      Parkin PC, Khambalia A, Kmet L, Macarthur C. Influence of socioeconomic status on the effectiveness of bicycle helmet legislation for children: a prospective observational study. Pediatrics 2003; 112:e192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13225/abstract/57\">",
"      Gilchrist J, Schieber RA, Leadbetter S, Davidson SC. Police enforcement as part of a comprehensive bicycle helmet program. Pediatrics 2000; 106:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13225/abstract/58\">",
"      Berg P, Westerling R. Bicycle helmet use among schoolchldren--the influence of parental involvement and children's attitudes. Inj Prev 2001; 7:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13225/abstract/59\">",
"      Forjuoh SN, Fiesinger T, Schuchmann JA, Mason S. Helmet use: a survey of 4 common childhood leisure activities. Arch Pediatr Adolesc Med 2002; 156:656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13225/abstract/60\">",
"      Chen J, Kresnow MJ, Simon TR, Dellinger A. Injury-prevention counseling and behavior among US children: results from the second Injury Control and Risk Survey. Pediatrics 2007; 119:e958.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13225/abstract/61\">",
"      Rodgers GB. Bicycle helmet use patterns among children. Pediatrics 1996; 97:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13225/abstract/62\">",
"      Miller PA, Binns HJ, Christoffel KK. Children's bicycle helmet attitudes and use. Association with parental rules. The Pediatric Practice Research Group. Arch Pediatr Adolesc Med 1996; 150:1259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13225/abstract/63\">",
"      Bernstein JD, Harper MA, Pardi LA, Christopher NC. Parental knowledge and children's use of bicycle helmets. Clin Pediatr (Phila) 2003; 42:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13225/abstract/64\">",
"      Cushman R, James W, Waclawik H. Physicians promoting bicycle helmets for children: a randomized trial. Am J Public Health 1991; 81:1044.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13225/abstract/65\">",
"      Loubeau PR. Exploration of the barriers to bicycle helmet use among 12 and 13 year old children. Accid Anal Prev 2000; 32:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13225/abstract/66\">",
"      Howland J, Sargent J, Weitzman M, et al. Barriers to bicycle helmet use among children. Results of focus groups with fourth, fifth, and sixth graders. Am J Dis Child 1989; 143:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13225/abstract/67\">",
"      Everett SA, Shults RA, Barrios LC, et al. Trends and subgroup differences in transportation-related injury risk and safety behaviors among high school students, 1991-1997. J Adolesc Health 2001; 28:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13225/abstract/68\">",
"      Eaton DK, Kann L, Kinchen S, et al. Youth risk behavior surveillance - United States, 2011. MMWR Surveill Summ 2012; 61:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13225/abstract/69\">",
"      American Academy of Pediatrics. Committee on Injury and Poison Prevention.. Bicycle helmets. Pediatrics 2001; 108:1030.",
"     </a>",
"    </li>",
"    <li>",
"     Healthy People 2020. Injury and violence prevention. file://www.healthypeople.gov/2020/topicsobjectives2020/objectiveslist.aspx?topicid=24 (Accessed on January 05, 2011).",
"    </li>",
"    <li>",
"     Safety Standard for Bicycle Helmets. 63 Federal Register 11711-11747 (1998) (codified at 16 CFR, section 1203).",
"    </li>",
"    <li>",
"     Bicycle Helmet Safety Institute. Bicycle Helmets for the 2008 Season. Available at: www.helmets.org/helmet08.htm (Accessed on February 01, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13225/abstract/73\">",
"      Rivara FP, Astley SJ, Clarren SK, et al. Fit of bicycle safety helmets and risk of head injuries in children. Inj Prev 1999; 5:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13225/abstract/74\">",
"      Parkinson GW, Hike KE. Bicycle helmet assessment during well visits reveals severe shortcomings in condition and fit. Pediatrics 2003; 112:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13225/abstract/75\">",
"      Liller KD, Nearns J, Cabrera M, et al. Children's bicycle helmet use and injuries in Hillsborough County, Florida before and after helmet legislation. Inj Prev 2003; 9:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13225/abstract/76\">",
"      Macpherson AK, To TM, Macarthur C, et al. Impact of mandatory helmet legislation on bicycle-related head injuries in children: a population-based study. Pediatrics 2002; 110:e60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13225/abstract/77\">",
"      Leblanc JC, Beattie TL, Culligan C. Effect of legislation on the use of bicycle helmets. CMAJ 2002; 166:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13225/abstract/78\">",
"      Macpherson A, Spinks A. Bicycle helmet legislation for the uptake of helmet use and prevention of head injuries. Cochrane Database Syst Rev 2007; :CD005401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13225/abstract/79\">",
"      Kendrick D, Royal S, Lids for Kids project team. Cycle helmet ownership and use; a cluster randomised controlled trial in primary school children in deprived areas. Arch Dis Child 2004; 89:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13225/abstract/80\">",
"      Rivara FP, Thompson DC, Thompson RS, et al. The Seattle children's bicycle helmet campaign: changes in helmet use and head injury admissions. Pediatrics 1994; 93:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13225/abstract/81\">",
"      McLaughlin KA, Glang A. The effectiveness of a bicycle safety program for improving safety-related knowledge and behavior in young elementary students. J Pediatr Psychol 2010; 35:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13225/abstract/82\">",
"      Owen R, Kendrick D, Mulvaney C, et al. Non-legislative interventions for the promotion of cycle helmet wearing by children. Cochrane Database Syst Rev 2011; :CD003985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13225/abstract/83\">",
"      Bishai D, Qureshi A, Cantu N, Parks C. Contracting with children and helmet distribution in the emergency department to improve bicycle helmet use. Acad Emerg Med 2003; 10:1371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13225/abstract/84\">",
"      Logan P, Leadbetter S, Gibson RE, et al. Evaluation of a bicycle helmet giveaway program--Texas, 1995. Pediatrics 1998; 101:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13225/abstract/85\">",
"      Kim AN, Rivara FP, Koepsell TD. Does sharing the cost of a bicycle helmet help promote helmet use? Inj Prev 1997; 3:38.",
"     </a>",
"    </li>",
"    <li>",
"     DiGuiseppi C. Preventing household/recreational injuries. In: Guide to Clinical Preventive Services. Report of the U.S. Preventive Services Task Force, 2nd ed, DiGuiseppi C, Atkins D, Woolf SH, Kamerow DB (Eds), Lippincott Williams &amp; Wilkins, Baltimore 1996. p.659.",
"    </li>",
"    <li>",
"     Committee on Injury and Poison Prevention, American Academy of Pediatrics. Recreational activities and vehicles. In: Injury Prevention and Control for Children and Youth, 3rd ed, Widome MD (Ed), American Academy of Pediatrics, Elk Grove Village, IL 1997. p.339.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13225/abstract/88\">",
"      Pucher J, Dijkstra L. Promoting safe walking and cycling to improve public health: lessons from The Netherlands and Germany. Am J Public Health 2003; 93:1509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13225/abstract/89\">",
"      Schubert J. Bike dangers. Pediatrics 1993; 92:882.",
"     </a>",
"    </li>",
"    <li>",
"     American Association of State Highway and Transportation Officials. 1981 Guide for Development of New Bicycle Facilities. In: Cycling Transportation Engineering, MIT Press, Cambridge, MA 1983.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13225/abstract/91\">",
"      G&aring;rder P, Leden L, Thed&eacute;en T. Safety implications of bicycle paths at signalized intersections. Accid Anal Prev 1994; 26:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13225/abstract/92\">",
"      Pucher J, Dill J, Handy S. Infrastructure, programs, and policies to increase bicycling: an international review. Prev Med 2010; 50 Suppl 1:S106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13225/abstract/93\">",
"      Thompson NJ, Sleet D, Sacks JJ. Increasing the use of bicycle helmets: lessons from behavioral science. Patient Educ Couns 2002; 46:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13225/abstract/94\">",
"      Dannenberg AL, Gielen AC, Beilenson PL, et al. Bicycle helmet laws and educational campaigns: an evaluation of strategies to increase children's helmet use. Am J Public Health 1993; 83:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13225/abstract/95\">",
"      Injury-Control Recommendations: Bicycle helmets. MMWR Recomm Rep 1995; 44(RR-1):1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13225/abstract/96\">",
"      Sargent JD, Peck MG, Weitzman M. Bicycle-mounted child seats. Injury risk and prevention. Am J Dis Child 1988; 142:765.",
"     </a>",
"    </li>",
"    <li>",
"     Recreational Activities and Vehicles. In: Injury Prevention and Control for Children and Youth, Widome MD (Ed), American Academy of Pediatrics, Elk Grove Village, IL 1997. p.339.",
"    </li>",
"    <li>",
"     Dershewitz RA. Environmental influences on children. In: Ambulatory Pediatric Care, 2nd ed, Dershewitz RA (Ed), Lippincott Company, Philadelphia 1993. p.88.",
"    </li>",
"    <li>",
"     U.S. Consumer Product Safety Commission. Age Determination Guidelines: Relating Children's Ages to Toy Characteristics and Play Behavior, Smith TP (Ed), September 2002. www.cpsc.gov/businfo/adg.pdf (Accessed on May 29, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13225/abstract/100\">",
"      Cheng TL, Fields CB, Brenner RA, et al. Sports injuries: An important cause of morbidity in urban youth. District of Columbia Child/Adolescent Injury Research Network. Pediatrics 2000; 105:E32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13225/abstract/101\">",
"      Cheng TL. Counseling about bicycle safety. Pediatr Rev 2001; 22:321.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Pediatrcs. Bicycle safety for the school age child: Ages 5-12. In: Caring for Your School-age Child: Ages 5-12, Schor EL (Ed), Bantam, 1999 1999.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13225/abstract/103\">",
"      Thompson DC, Thompson RS, Rivara FP. Incidence of bicycle-related injuries in a defined population. Am J Public Health 1990; 80:1388.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2859 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-3548BCC041-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_58_13225=[""].join("\n");
var outline_f12_58_13225=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      SCOPE OF THE PROBLEM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Epidemiology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Types of injuries",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Socioeconomic impact",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      PREVENTION OF BICYCLE-RELATED INJURIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Bicycle helmet use",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Helmet specifications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Helmet fit",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Bicycle safety programs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Bicycle paths",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      CLINICIAN'S ROLE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Anticipatory guidance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Children &lt;1 year",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Children 1-5 years",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Children 6-12 years",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      RESOURCES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/2859\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/2859|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?34/23/35198\" title=\"figure 1\">",
"      Bicycle helmet fit",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/31/11767?source=related_link\">",
"      Overview of pediatric injury prevention: Epidemiology; history; application",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?13/44/14020?source=related_link\">",
"      Patient information: Head injury in children and adolescents (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/53/35669?source=related_link\">",
"      Straddle injuries",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_58_13226="General principles on the treatment of early stage and locally advanced breast cancer in older women";
var content_f12_58_13226=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   General principles on the treatment of early stage and locally advanced breast cancer in older women",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/58/13226/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/58/13226/contributors\">",
"     Gretchen Kimmick, MD, MS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/58/13226/contributors\">",
"     Pearl H Seo, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/58/13226/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/58/13226/contributors\">",
"     Daniel F Hayes, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/58/13226/contributors\">",
"     Kenneth E Schmader, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/58/13226/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/58/13226/contributors\">",
"     Don S Dizon, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/58/13226/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 3, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;For most women, increasing age is the primary risk factor for breast cancer. Of the approximately 230,000 new cases of female breast cancer diagnosed annually in the United States, almost one-half arise in older women (typically defined as age &ge;65 years, though this varies in studies).",
"   </p>",
"   <p>",
"    This topic will review general principles on the treatment of early stage and locally advanced breast cancer in older women. An overview of the approach to women with newly diagnosed breast cancer and the treatment of breast cancer that applies to all women regardless of age are discussed separately.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/46/19177?source=see_link\">",
"       \"Overview of the treatment of newly diagnosed, non-metastatic breast cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/18/12586?source=see_link\">",
"       \"Mastectomy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/42/31402?source=see_link\">",
"       \"Breast conserving therapy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/52/42825?source=see_link\">",
"       \"Management of the regional lymph nodes in breast cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/7/11385?source=see_link\">",
"       \"Role of radiation therapy in breast conservation therapy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/46/39657?source=see_link\">",
"       \"Techniques of breast and chest wall irradiation for early stage breast cancer\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/55/42873?source=see_link\">",
"       \"Radiation techniques for locally advanced breast cancer\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/3/41017?source=see_link\">",
"       \"Postmastectomy chest wall irradiation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/40/20106?source=see_link\">",
"       \"Adjuvant endocrine therapy for hormone receptor-positive breast cancer\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/4/37961?source=see_link\">",
"       \"Adjuvant chemotherapy for hormone receptor-positive or negative, HER2-negative breast cancer\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/7/11384?source=see_link\">",
"       \"Adjuvant medical therapy for HER2-positive breast cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/40/35466?source=see_link\">",
"       \"Neoadjuvant therapy for breast cancer: Rationale, pretreatment evaluation, and therapeutic options\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/31/1529?source=see_link\">",
"       \"Neoadjuvant systemic therapy for breast cancer: Response, subsequent treatment, and prognosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H184390246\">",
"    <span class=\"h1\">",
"     TREATMENT PATTERNS OF OLDER WOMEN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following a new diagnosis of breast cancer, older women often receive less than standard therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13226/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]. In the largest study, which involved over 120,000 women, increasing age was associated with the following treatment trends [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13226/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Decreased surgical rates &mdash; While over 93 percent of women &lt;80 years underwent surgery, the surgical rates were 83, 65, and 41 percent for women 80 to 84, 85 to 89, and &ge;90 years, respectively.",
"     </li>",
"     <li>",
"      Less frequent use of adjuvant radiation therapy (RT) following breast conservation surgery &mdash; RT was administered in &gt;90, 86, 71, 36, and 15 percent of women &lt;75 years, 75 to 69, 80 to 84, 85 to 89, and &ge;90 years. However, whether RT recommendations varied according to prognostic factors (eg, tumor size, hormone receptor status) was not reported.",
"     </li>",
"     <li>",
"      Increased use of primary endocrine therapy &mdash; Primary endocrine therapy (without surgical treatment) was administered in a higher proportion of women as age increased. This ranged from &lt;1 percent among women less than 65 years to 47 percent among women 90 years or older.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Variations in treatment patterns among older and younger women may be due to differences in breast cancer features, presence of competing comorbidities and the general health status of women. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Factors that affect treatment decisions'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In addition, older women have generally not participated in clinical trials evaluating the treatment of breast cancer, partially due to comorbidities that can exclude them from protocol therapy. As a result, there is a lack of evidence-based guidelines to inform the treatment of breast cancer in this population.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     FACTORS THAT AFFECT TREATMENT DECISIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differences in tumor biology and overall general health between older and younger women with breast cancer often play a role in decisions regarding treatment. These are discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H518871776\">",
"    <span class=\"h2\">",
"     Tumor biology",
"    </span>",
"    &nbsp;&mdash;&nbsp;In several studies, breast cancers diagnosed in older women have less aggressive biologic features compared to the breast cancers that occur in younger women [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13226/abstract/6-9\">",
"     6-9",
"    </a>",
"    ]. As an example, in a combined series of women aged 55 or older with breast cancer derived from the San Antonio Breast Cancer Database (n=35,154) and the Surveillance, Epidemiology and End Results (SEER) registry (n=171,424), breast cancers diagnosed in older women had lower proliferative indices, normal p53 expression, and diploid DNA, compared to the cancers diagnosed in younger women [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13226/abstract/7\">",
"     7",
"    </a>",
"    ]. Other differences include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Higher rates of hormone receptor expression &mdash; Breast cancers in older women express estrogen (ER)",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      progesterone (PR) receptors more often than those of younger women (85 versus 70 percent in women &ge;65 versus &lt;50 years, respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?12/58/13226/abstract/6-8,10\">",
"       6-8,10",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/47/19194?source=see_link\">",
"       \"Hormone receptors in breast cancer: Clinical utility and guideline recommendations to improve test accuracy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Lower rates of HER2 overexpression &mdash; Amplification",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      overexpression of the human epidermal growth factor 2 receptor (HER2-positivity) is less commonly seen in older women; in one series, the proportion of cases that were HER2-positive was 4 versus 9 percent among women over 60 years compared to those &le;35 years [",
"      <a class=\"abstract\" href=\"UTD.htm?12/58/13226/abstract/11\">",
"       11",
"      </a>",
"      ]. However, as in younger women, overexpression is associated with an adverse prognosis [",
"      <a class=\"abstract\" href=\"UTD.htm?12/58/13226/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Higher proportion of low-risk tumor histologies &mdash; As in younger women, infiltrating ductal carcinoma is the most common histologic type of breast cancer in the elderly population. However, more indolent breast cancers (eg, mucinous and papillary carcinomas) are encountered more often with advancing age [",
"      <a class=\"abstract\" href=\"UTD.htm?12/58/13226/abstract/7,13,14\">",
"       7,13,14",
"      </a>",
"      ]. As an example, mucinous carcinomas represent between four and six percent of breast cancers in women older than 75 years; in contrast, they represent only one percent of cases in premenopausal women [",
"      <a class=\"abstract\" href=\"UTD.htm?12/58/13226/abstract/7,15\">",
"       7,15",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/42/16040?source=see_link\">",
"       \"Pathology of breast cancer\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H518872214\">",
"    <span class=\"h2\">",
"     General health status",
"    </span>",
"    &nbsp;&mdash;&nbsp;Life expectancy, comorbidity, and functional status are important factors to consider when making treatment decisions in elderly cancer patients. In general, advancing age is associated with reduced tolerance to physiologic stress, higher prevalence of comorbidity, reduced social support (eg, access to transportation), and cognitive impairment [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13226/abstract/16\">",
"     16",
"    </a>",
"    ]. Any of these factors can alter the balance of risks and the potential benefits of treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Life expectancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Breast cancer does not necessarily lead to death in older women. Therefore, the life expectancy of a woman should be considered when formulating treatment plans. Tools that estimate life expectancy, such as",
"    <a class=\"external\" href=\"file://www.eprognosis.org/\">",
"     ePrognosis",
"    </a>",
"    , may be particularly useful in this regard, particularly for women with early stage disease.",
"   </p>",
"   <p>",
"    The impact of a breast cancer diagnosis on life expectancy was addressed in a study that used the linked SEER-Medicare data set to compare the survival of 66,000 women 67 years of age and older who were diagnosed with breast cancer, with that of controls without breast cancer matched for age, comorbidity, prior mammography use, and social demographics [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13226/abstract/17\">",
"     17",
"    </a>",
"    ]. The main results with a median follow-up of eight years were:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Women diagnosed with ductal carcinoma in situ (DCIS) or stage I invasive breast cancer had a lower risk of death compared to controls (adjusted HR [HR] 0.7, 95% CI 0.7-0.7 for DCIS; HR 0.8, 95% CI 0.8-0.8 for stage I breast cancer). Cardiovascular disease was the most common cause of death in these women.",
"     </li>",
"     <li>",
"      Women diagnosed with stage II disease or higher had an increased risk of death compared to controls (HR 1.2, 95% CI 1.2-1.2), regardless of age. However, among women &ge;80 years diagnosed with stage II breast cancer, cardiovascular disease was still the most common cause of death.",
"     </li>",
"     <li>",
"      For women with stage III or IV breast cancer, breast cancer was the most common cause of death.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Comorbidity",
"    </span>",
"    &nbsp;&mdash;&nbsp;For women with breast cancer, life expectancy is almost halved in the presence of comorbidity, such as a prior myocardial infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13226/abstract/18\">",
"     18",
"    </a>",
"    ]. Comorbidity is characterized as the number and effect of an individual's other physical and psychological diseases in addition to the condition for which he or she is seeking treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13226/abstract/19\">",
"     19",
"    </a>",
"    ]. The presence of comorbidity is independently associated with decreased life expectancy, and plays a major role in determining survival in older patients with cancer. (See",
"    <a class=\"local\" href=\"#H518872251\">",
"     'Functional status'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Comorbid conditions that impose functional limitations are associated with higher mortality (from breast cancer and non-breast cancer causes), particularly if they are expected to worsen over time (eg, diabetes with end-organ damage, steroid- or oxygen-dependent chronic obstructive pulmonary disease, or dementia) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13226/abstract/20-22\">",
"     20-22",
"    </a>",
"    ]. In one study of over 64,000 women with breast cancer (median age 75), the adjusted HR of death (from all causes), increased as the severity of comorbidity increased (measured using the Charlson Comorbidity Index Score (",
"    <a class=\"graphic graphic_table graphicRef72047 \" href=\"UTD.htm?25/40/26252\">",
"     table 1",
"    </a>",
"    )) compared to patients with no comorbidity [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13226/abstract/20\">",
"     20",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Index score 1 &mdash; HR 1.45 (95% CI 1.41-1.48)",
"     </li>",
"     <li>",
"      Index score 2 &mdash; HR 2.12 (95% CI 2.05-2.20)",
"     </li>",
"     <li>",
"      Index score &ge;3 &mdash; HR 3.19 (95% CI 3.06-3.32)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These data emphasize the importance of comorbidity in the treatment of older women with breast cancer. Therefore, all older women should undergo a pretreatment evaluation including an assessment of organ function and comorbidity, which may impact on the ability of patients to tolerate surgery or anti-cancer therapies and in particular, chemotherapy. A discussion on organ function in older women is covered separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/42/10922?source=see_link\">",
"     \"Systemic chemotherapy for cancer in elderly persons\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H518872251\">",
"    <span class=\"h3\">",
"     Functional status",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with a poor functional status may be at greater risk of death from a cause other than breast cancer, which suggests that such patients may not benefit from breast cancer treatment, especially adjuvant systemic therapy.",
"   </p>",
"   <p>",
"    Functional status refers to one's ability to perform routine daily tasks. As with comorbidity, the presence of functional limitations is independently associated with worse life expectancy (from any cause) and plays a major role in determining overall survival in older patients, although it does not necessarily impact breast cancer specific survival. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Comorbidity'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The impact of functional status was shown in a study of 2202 women with breast cancer who had completed adjuvant treatment and provided information on endurance, muscular range of motion, and dexterity [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13226/abstract/23\">",
"     23",
"    </a>",
"    ]. The presence of functional limitations was significantly associated with older age, less education, and obesity. With a median follow-up of nine years, patients with functional limitations had an increased risk of death from all causes (HR 1.40, 95% CI 1.03-1.92) and competing causes (HR 2.60, 95% CI 1.69-3.98), but not from breast cancer (HR 0.90, 95% CI 0.64-1.26).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H518874633\">",
"    <span class=\"h3\">",
"     Frailty",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among older patients with breast cancer, frailty is associated with an increased risk of treatment-related complications, including a higher likelihood of requiring hospitalization, and decreased overall survival [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13226/abstract/24\">",
"     24",
"    </a>",
"    ]. Frailty is characterized by decreased reserve and diminished resistance to stressors, which results from cumulative declines across multiple physiologic systems, and can lead to increased susceptibility to adverse outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13226/abstract/25\">",
"     25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/7/28792?source=see_link\">",
"     \"Frailty\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A reasonable definition of frailty comes from the Cardiovascular Health Study index, which identified frailty criteria in a longitudinal study of over 750 adults aged 70 and older [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13226/abstract/24\">",
"     24",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Weight loss &ge;5 percent in last year",
"     </li>",
"     <li>",
"      Slow walking speed (&gt;6 to 7 seconds to walk 15 feet)",
"     </li>",
"     <li>",
"      Decreased physical activity (&lt;383 Kcals in males and &lt;270 Kcals in females spent per week)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     COMPREHENSIVE GERIATRIC ASSESSMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;For women over 65 years, a comprehensive geriatric assessment (CGA) (",
"    <a class=\"graphic graphic_table graphicRef71535 \" href=\"UTD.htm?6/54/7020\">",
"     table 2",
"    </a>",
"    ) may help physicians develop a coordinated plan for breast cancer treatment. However, it is time consuming and may not be practical for all patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/56/41864?source=see_link\">",
"     \"Comprehensive geriatric assessment for patients with cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As a result, some experts prefer the use of a screening tool (assessment of autonomy, malnutrition, depression, cognition, and comorbidity) to identify vulnerable patients for whom a CGA could potentially optimize their cancer treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13226/abstract/26\">",
"     26",
"    </a>",
"    ], while others employ a self-administered CGA assessment tool such as the one illustrated in the following (",
"    <a class=\"graphic graphic_table graphicRef70657 \" href=\"UTD.htm?2/27/2492\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13226/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     TREATMENT APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest the following approach to the treatment of older women:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For healthy older women, we recommend treatment as one would for a younger woman with breast cancer. In general, healthy older women tolerate breast cancer treatment as well as younger patients and are not at increased risk for complications (solely on the basis of advanced age) [",
"      <a class=\"abstract\" href=\"UTD.htm?12/58/13226/abstract/28\">",
"       28",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H184391652\">",
"       'Medically fit'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      For medically frail patients (eg, those with cognitive impairment, frailty,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      those with comorbidities), treatment depends on whether or not surgery is an option (see",
"      <a class=\"local\" href=\"#H184391833\">",
"       'Medically frail'",
"      </a>",
"      below):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For patients who are surgical candidates, we prefer surgical resection of the primary tumor rather than medical therapy. In most cases, these patients can be observed after surgery and may not require further therapy. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Breast surgery'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      For patients who refuse surgery and those patients who are not surgical candidates, we offer primary medical therapy based on the primary tumor features. However, for women with a limited life expectancy (due to comorbidities) and those who wish to avoid treatment-related toxicity, we proceed with supportive care and referral for palliative care services. (See",
"      <a class=\"local\" href=\"#H1725156589\">",
"       'Patients who are not surgical candidates'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Primary radiation therapy should not be administered. (See",
"      <a class=\"local\" href=\"#H20723014\">",
"       'Primary radiation therapy'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The approach to systemic therapy in older women depends on the individual patient&rsquo;s general health status, whether surgery was performed, and the presence of risk factors (eg, high tumor grade, pathologic nodal involvement, presence of angiolymphatic invasion, or high risk gene expression analysis). The options for systemic treatment include chemotherapy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    endocrine therapy. For women with HER2-positive breast cancers, this also includes the use of HER2-directed agents (ie,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    ). The use of these modalities is reviewed below. (See",
"    <a class=\"local\" href=\"#H1734265603\">",
"     'Adjuvant therapy'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H1725156589\">",
"     'Patients who are not surgical candidates'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H184391652\">",
"    <span class=\"h1\">",
"     MEDICALLY FIT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment approach to healthy older women with newly diagnosed non-metastatic breast cancer is identical to that of younger women and should include surgery for removal of cancer from the breast, axillary assessment (if indicated), RT (if indicated by type of surgery and cancer size and stage), and systemic adjuvant treatment (depending on the tumor characteristics and recurrence risk). A brief discussion of these options as it relates to older women specifically is covered below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Breast surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;A similar approach to breast cancer surgery should be used in medically fit women, regardless of age. Most older women are likely to choose breast conservation surgery over mastectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13226/abstract/29\">",
"     29",
"    </a>",
"    ]. In addition, breast conserving surgery results in less disability in older women [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13226/abstract/30\">",
"     30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/44/43719?source=see_link\">",
"     \"Functional problems in the patient with cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/18/12586?source=see_link\">",
"     \"Mastectomy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/42/31402?source=see_link\">",
"     \"Breast conserving therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with large tumors that cannot be treated by breast conserving surgery are best treated by mastectomy. However, preoperative (neoadjuvant) systemic therapy is an approach for some patients, especially if they are interested in breast conserving therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13226/abstract/31\">",
"     31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/46/19177?source=see_link\">",
"     \"Overview of the treatment of newly diagnosed, non-metastatic breast cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/40/35466?source=see_link\">",
"     \"Neoadjuvant therapy for breast cancer: Rationale, pretreatment evaluation, and therapeutic options\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Management of the axilla",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical evaluation of the axilla should be reserved for patients in whom the prognostic information will be used for making treatment decisions. The surgical options for the axilla are identical to those offered to younger women. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/52/42825?source=see_link\">",
"     \"Management of the regional lymph nodes in breast cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/47/36602?source=see_link\">",
"     \"Sentinel lymph node dissection for breast cancer: Indications and outcomes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Role of radiation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;For healthy older women, adjuvant RT is indicated following breast conserving surgery and in selected women following mastectomy. RT is generally well tolerated and the cosmetic results are excellent, even in older women [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13226/abstract/32\">",
"     32",
"    </a>",
"    ]. However, the risk of a local recurrence is lower in older women, and the benefits of RT following breast conservation surgery may decline with age [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13226/abstract/33,34\">",
"     33,34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Therefore, some older women may not require adjuvant RT, particularly those who are over the age of 70 with small (&lt;2 cm) estrogen receptor-positive breast cancer, no evidence of nodal disease (either clinically or pathologically confirmed), and agree to take adjuvant endocrine therapy. Patients who prefer not to proceed with adjuvant RT should be counselled that they may have a slightly higher risk of an in-breast cancer recurrence compared to those who undergo RT. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/7/11385?source=see_link&amp;anchor=H9#H9\">",
"     \"Role of radiation therapy in breast conservation therapy\", section on 'Older women receiving adjuvant endocrine therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The role of RT in the treatment of breast cancer is discussed separately:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/7/11385?source=see_link\">",
"       \"Role of radiation therapy in breast conservation therapy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/3/41017?source=see_link\">",
"       \"Postmastectomy chest wall irradiation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/46/39657?source=see_link\">",
"       \"Techniques of breast and chest wall irradiation for early stage breast cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/27/12728?source=see_link\">",
"       \"Accelerated partial breast irradiation\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1734265603\">",
"    <span class=\"h2\">",
"     Adjuvant therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The options for systemic treatment include chemotherapy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    endocrine therapy. In addition, HER2-directed treatment should be a part of the treatment for women with HER2-positive breast cancers. The approach to adjuvant systemic therapy is illustrated in a table (",
"    <a class=\"graphic graphic_table graphicRef81185 \" href=\"UTD.htm?41/56/42892\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H184392052\">",
"    <span class=\"h3\">",
"     Chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The same principles that guide the use of adjuvant systemic therapy in younger individuals also apply to medically fit older women. In general, we prefer to administer an anthracycline-",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    taxane-based regimen in medically fit women. However, the benefit of treatment must be balanced by the risks of anthracycline-based therapy, especially heart damage [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13226/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. As previously discussed, the presence of comorbidity should be taken into account, especially if adjuvant chemotherapy is being considered [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13226/abstract/37\">",
"     37",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Comorbidity'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/4/37961?source=see_link\">",
"     \"Adjuvant chemotherapy for hormone receptor-positive or negative, HER2-negative breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Following chemotherapy, all patients with hormone receptor-positive breast cancer should also receive endocrine therapy. (See",
"    <a class=\"local\" href=\"#H518875797\">",
"     'Endocrine therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H518876098\">",
"    <span class=\"h4\">",
"     Anthracycline-containing regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anthracycline-containing adjuvant therapy (preferably in combination with a taxane) is the standard regimen for most women who are candidates for adjuvant chemotherapy, irrespective of age. This is based on the positive benefits of these regimens on breast cancer outcomes compared to non-anthracycline based treatment (ie,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    , and 5-fluorouracil [CMF]) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13226/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/4/37961?source=see_link&amp;anchor=H3291201#H3291201\">",
"     \"Adjuvant chemotherapy for hormone receptor-positive or negative, HER2-negative breast cancer\", section on 'The Early Breast Cancer Trialists' Collaborative Group (EBCTCG) Meta-Analysis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, for older patients, it is important to consider the superimposed risks associated with administration of an anthracycline. This was shown in a study using",
"    <span class=\"nowrap\">",
"     SEER/Medicare",
"    </span>",
"    database that included 43,338 women aged 66 to 80 with stage I to III breast cancer with no history of preexisting heart failure [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13226/abstract/35\">",
"     35",
"    </a>",
"    ]. Over 4700 women received an anthracycline-containing chemotherapy regimen, while almost 4000 received a non-anthracycline containing regimen; 34,705 women received no chemotherapy. At a median follow-up of 56 months, the following heart failure rates were reported at five and ten years:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For women treated with anthracyclines: 19 and 38 percent, respectively",
"     </li>",
"     <li>",
"      For women treated without an anthracycline: 18 and 33 percent",
"     </li>",
"     <li>",
"      For women not treated with chemotherapy: 15 and 29 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Besides age, other baseline characteristics associated with the development of heart failure included black race, hypertension, diabetes, and coronary artery disease. However, this study demonstrated that chemotherapy increases the risk of congestive heart failure and that an anthracycline increased this risk as far out as ten years later.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/27/4536?source=see_link\">",
"     Epirubicin",
"    </a>",
"    may be less cardiotoxic than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    , and some clinicians prefer epirubicin for use in older patients. Recommended maximum doses based upon the presence of risk factors other than epirubicin are presented in the following table (",
"    <a class=\"graphic graphic_table graphicRef56455 \" href=\"UTD.htm?31/54/32621\">",
"     table 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13226/abstract/40\">",
"     40",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/46/41706?source=see_link&amp;anchor=H18#H18\">",
"     \"Cardiotoxicity of anthracycline-like chemotherapy agents\", section on 'Epirubicin'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H518876105\">",
"    <span class=\"h4\">",
"     Docetaxel plus cyclophosphamide",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients who are not candidates for an anthracycline, we administer",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    (TC) (",
"    <a class=\"graphic graphic_table graphicRef56545 \" href=\"UTD.htm?2/43/2750\">",
"     table 6",
"    </a>",
"    ). This is based on one randomized trial showing that TC results in a higher disease free and overall survival compared to AC among women with stage I to III breast cancer (16 percent of whom were 65 years or older) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13226/abstract/41\">",
"     41",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/4/37961?source=see_link&amp;anchor=H27692287#H27692287\">",
"     \"Adjuvant chemotherapy for hormone receptor-positive or negative, HER2-negative breast cancer\", section on 'Is an anthracycline necessary?'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1734265746\">",
"    <span class=\"h4\">",
"     Other regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients who are not candidates for either anthracyclines or taxanes, oral CMF is a reasonable option. Despite its oral availability (and thus potentially a more attractive and convenient regimen), it is associated with a higher risk of serious (grade 3) toxicity including hematologic and mucosal toxicity in women &ge;65 years compared to younger women [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13226/abstract/42,43\">",
"     42,43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We do not recommend",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    monotherapy as adjuvant chemotherapy regimens in older women with early-stage breast cancer. In the Cancer and Leukemia Group B 49907 trial, women aged 65 years or older were treated with AC or capecitabine, per clinical choice [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13226/abstract/44\">",
"     44",
"    </a>",
"    ]. Based upon analysis of 633 women enrolled and followed for a median duration of 2.4 years, capecitabine resulted in a lower rate of relapse free survival (68 versus 85 percent with AC) and overall survival (86 versus 91 percent) at three years.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H518875665\">",
"    <span class=\"h3\">",
"     HER2-directed agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;For fit older women with HER2-overexpressing breast cancer who have undergone surgery, we recommend adjuvant",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    plus systemic therapy rather than adjuvant systemic therapy alone. Combined treatment significantly improves survival and diminishes recurrence risk.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      For patients who are candidates for adjuvant chemotherapy, we suggest",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/59/41913?source=see_link\">",
"       docetaxel",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      , plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"       trastuzumab",
"      </a>",
"      , due to its more favorable safety profile with respect to cardiotoxicity [",
"      <a class=\"abstract\" href=\"UTD.htm?12/58/13226/abstract/45\">",
"       45",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/7/11384?source=see_link\">",
"       \"Adjuvant medical therapy for HER2-positive breast cancer\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      For those patients with hormone receptor-positive breast cancer, HER2-directed treatment can be combined with endocrine therapy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/40/20106?source=see_link&amp;anchor=H659778#H659778\">",
"       \"Adjuvant endocrine therapy for hormone receptor-positive breast cancer\", section on 'Patients with HER2-positive tumors'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The administration of HER2-directed therapy plus chemotherapy is associated with a small but real increase in the risk of myocardial dysfunction, particularly if an anthracycline-based regimen is administered. Therefore, the risk associated with combined treatment must be balanced against the prognosis of women with newly diagnosed breast cancer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/7/11384?source=see_link&amp;anchor=H2718616#H2718616\">",
"     \"Adjuvant medical therapy for HER2-positive breast cancer\", section on 'Assessing risks and benefits of treatment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/12/40138?source=see_link\">",
"     \"Cardiotoxicity of nonanthracycline cancer chemotherapy agents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/46/41706?source=see_link\">",
"     \"Cardiotoxicity of anthracycline-like chemotherapy agents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H518875797\">",
"    <span class=\"h3\">",
"     Endocrine therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adjuvant endocrine therapy should be offered to all women with ER-positive breast tumors &gt;1 cm, regardless of age, provided they are candidates for medical therapy. We prefer to administer an aromatase inhibitor (AI) in older women because of the benefits of its benefits in the adjuvant setting compared to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    . However, for women at risk for cardiovascular complications or bone loss, and those unable to tolerate an AI due to toxicity, tamoxifen alone is a reasonable alternative. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/40/20106?source=see_link\">",
"     \"Adjuvant endocrine therapy for hormone receptor-positive breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     Tamoxifen",
"    </a>",
"    has been compared to observation only, while the trials of an AI have been compared to tamoxifen. Representative findings include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"       Tamoxifen",
"      </a>",
"      significantly improves breast cancer outcomes compared to observation alone, including ten-year risks of recurrence (23 versus 44 percent, respectively, p=0.001) and breast cancer-specific mortality (20 versus 37 percent, p=0.04) [",
"      <a class=\"abstract\" href=\"UTD.htm?12/58/13226/abstract/46\">",
"       46",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the 2010 Early Breast Cancer Trialists&rsquo; Group (EBCTCG) meta-analysis, adjuvant treatment with an AI for five years resulted in fewer recurrences compared to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      in women 60 to 69 years (12 versus 14 percent, RR 0.80) and in women 70 years or older (14 versus 17 percent, RR 0.78). &nbsp; [",
"      <a class=\"abstract\" href=\"UTD.htm?12/58/13226/abstract/47\">",
"       47",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As in younger women, the optimal duration of endocrine therapy use is not clear. A minimum duration of five years of endocrine therapy should be prescribed for most older women. However, longer durations up to ten years might be appropriate in selected patients, especially those with higher risk tumor features (eg, nodal involvement, higher tumor grade). The issue of duration of treatment is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/40/20106?source=see_link&amp;anchor=H38114838#H38114838\">",
"     \"Adjuvant endocrine therapy for hormone receptor-positive breast cancer\", section on 'Duration of endocrine treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H184391833\">",
"    <span class=\"h1\">",
"     MEDICALLY FRAIL",
"    </span>",
"    &nbsp;&mdash;&nbsp;For medically frail patients (eg, those with cognitive impairment or comorbidities), the risks of surgery, RT, chemotherapy, and endocrine therapy must be considered in the development of an individualized treatment plan. Women with a limited life expectancy and those who wish to avoid treatment-related toxicity should be offered supportive care and referral for palliative care services. (See",
"    <a class=\"local\" href=\"#H518874633\">",
"     'Frailty'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1725156207\">",
"    <span class=\"h2\">",
"     Surgical candidates",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients who are surgical candidates, we prefer surgical resection rather than medical therapy. Multiple studies of women with hormone receptor-positive breast cancer treated with either surgery alone or followed by endocrine therapy consistently showed improvements in the risks of recurrence with surgery compared to endocrine therapy alone, although a benefit in overall survival is less clear [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13226/abstract/48-50\">",
"     48-50",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H20722981\">",
"     'Surgery versus primary endocrine therapy in women with hormone receptor-positive disease'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    One tool that may assist in the determination of whether a patient is an appropriate surgical candidate is the Preoperative Assessment of Cancer in Elderly (PACE) comprised of a CGA (Comprehensive Geriatric Assessment), brief fatigue inventory, performance status, and Anesthesia Society of Anesthesiologists grade [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13226/abstract/51\">",
"     51",
"    </a>",
"    ]. In one prospective study, 460 older patients with cancer (47 percent had breast cancer) were evaluated, and those patients deemed to be in poor health (defined by the presence of moderate or severe fatigue, dependence with their instrumental activities of daily living, and poor performance status) were at significantly increased risk for postoperative complications and an extended hospital stay. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Comprehensive geriatric assessment'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Following surgery most patients can be offered observation, especially if their life expectancy is limited. For patients who desire subsequent treatment, adjuvant therapy can be administered using an approach similar to that used for medically frail patients who did not undergo surgery. (See",
"    <a class=\"local\" href=\"#H1725156589\">",
"     'Patients who are not surgical candidates'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20722981\">",
"    <span class=\"h3\">",
"     Surgery versus primary endocrine therapy in women with hormone receptor-positive disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;We favor surgery rather than primary endocrine therapy for women with hormone receptor-positive breast cancer because surgical resection of the breast cancer reduces the risk of a local recurrence, which in older women can be a source of significant morbidity. However, the impact of surgery on overall survival has not been clearly demonstrated.",
"   </p>",
"   <p>",
"    Our preference for surgery as the primary treatment is supported by multiple trials and a 2006 meta-analysis, which compared surgery (alone or followed by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    ) to tamoxifen as sole treatment for newly diagnosed breast cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13226/abstract/48\">",
"     48",
"    </a>",
"    ]. Compared to tamoxifen alone:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There was an improvement in progression-free survival favoring surgery alone (HR 0.55, 95% CI 0.39-0.77) or surgery plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      (HR 0.65, 95% CI 0.53-0.81).",
"     </li>",
"     <li>",
"      There was no statistically significant difference in overall survival for surgery alone (HR 0.98, 95% CI 0.74-1.30); however, there was trend towards an improvement in overall survival with surgery plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      (HR 0.86, 95% CI 0.73-1.00).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, two trials with extended follow-up and not included in the 2006 meta-analysis did not confirm the positive impact of surgery on overall survival: &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the Elderly Primary Series (EPS)-1 trial, 138 women &gt;70 years with breast cancer (&lt;5 cm in size, unselected for ER status) in a single surgeon&rsquo;s practice were randomly assigned to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      or wedge mastectomy as their only treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?12/58/13226/abstract/49\">",
"       49",
"      </a>",
"      ]. Median time to local recurrence was significantly longer for patients treated with mastectomy rather than with primary tamoxifen treatment (116 versus 48 months). At a median follow-up of 20 years, there was no difference in the incidence of regional recurrence (30 versus 37 percent in the tamoxifen versus mastectomy arms, respectively) or distant metastases (35 versus 42 percent). There was also no difference in overall survival (median, 73 versus 74 months).",
"     </li>",
"     <li>",
"      In the EPS-2 trial, 153 women &ge;70 with ER-positive, T1-2 N0-1 breast cancer were randomly assigned to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      as their only treatment or to mastectomy followed by tamoxifen [",
"      <a class=\"abstract\" href=\"UTD.htm?12/58/13226/abstract/50\">",
"       50",
"      </a>",
"      ]. Compared to tamoxifen alone, there was no significant difference in either breast cancer specific survival (89 versus 87 percent) or overall survival (64 versus 66 percent) compared to treatment with mastectomy followed by tamoxifen. However, there was a lower rate of recurrence at ten years (2 versus 43 percent, respectively).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based on the cumulative data, we prefer surgery to medical therapy in medically frail patients who are able to undergo this procedure. However, primary treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    is a reasonable alternative because there is no clear benefit in overall survivor favoring either approach.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1725156589\">",
"    <span class=\"h2\">",
"     Patients who are not surgical candidates",
"    </span>",
"    &nbsp;&mdash;&nbsp;For medically frail patients with breast cancer who are not candidates for surgery, including those who refuse surgery and desire treatment for breast cancer, we offer systemic therapy based on the primary tumor features:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with hormone-positive disease can be offered primary endocrine therapy. (See",
"      <a class=\"local\" href=\"#H1725156350\">",
"       'Primary endocrine therapy in hormone receptor-positive breast cancer'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Patients with hormone receptor-negative disease can be offered single agent chemotherapy using an approach similar to the treatment of women with metastatic breast cancer. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/20/32072?source=see_link\">",
"       \"Systemic treatment for metastatic breast cancer: Selection of chemotherapy regimen\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with HER2-positive disease (regardless of hormone receptor-status) can be offered treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/39/6776?source=see_link\">",
"       trastuzumab",
"      </a>",
"      (alone or in combination with single agent systemic therapy) using a similar approach to the treatment of women with HER2-positive metastatic breast cancer. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/43/22202?source=see_link\">",
"       \"Systemic treatment for metastatic breast cancer: Molecular targeted therapy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, for women with a limited life expectancy (due to comorbidities) and those who wish to avoid treatment and its associated toxicity, we proceed with supportive care and referral for palliative care services. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/6/29801?source=see_link\">",
"     \"Palliative care: Benefits, services, and models of care\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1725156350\">",
"    <span class=\"h3\">",
"     Primary endocrine therapy in hormone receptor-positive breast cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no randomized trials comparing endocrine therapy to more aggressive treatment (ie, chemotherapy) or to observation in women who did not undergo primary surgery for breast cancer; nor are there prospective studies evaluating",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    versus an AI in this population. However, based on the incremental benefits of an AI on survival outcomes compared to tamoxifen when administered in the adjuvant setting for women with postmenopausal breast cancer, we prefer an AI. Tamoxifen is a reasonable alternative, particularly in women who are at risk for toxicities from an AI (eg, due to pre-existing cardiovascular disease or osteopenia) or are unable to tolerate an AI due to side effects.",
"   </p>",
"   <p>",
"    Most data on the role of primary endocrine therapy come from retrospective studies. As examples: &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one series, 104 women with early stage breast cancer who were unwilling or unfit to undergo surgery opted for endocrine therapy (without surgery) and received",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/26/36261?source=see_link\">",
"       letrozole",
"      </a>",
"      (2.5 mg daily) [",
"      <a class=\"abstract\" href=\"UTD.htm?12/58/13226/abstract/52\">",
"       52",
"      </a>",
"      ]. The median age of patients was 83 years (range, 53 to 98 years). The reasons given for pursuing primary endocrine treatment were frailty (46 percent), comorbidities (29 percent), patient preference (16 percent), and older age (9 percent). Treatment with letrozole resulted in [",
"      <a class=\"abstract\" href=\"UTD.htm?12/58/13226/abstract/52\">",
"       52",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      An overall response rate of 82 percent with median time to initial response of 4 months (range, 2 to 24 months) and median time to best response of 9 months (range, 3 to 50 months). The median overall survival was 51 months (range, 4 to 103 months).",
"     </li>",
"     <li>",
"      A 12 percent incidence of fractures during treatment, most commonly involving the femur or wrist.",
"     </li>",
"     <li>",
"      Treatment was stopped due to disease progression in 18 percent. During a median follow-up of 56 months, 42 patients (40 percent) died, though only 12 (29 percent) died of breast cancer.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In another retrospective study, 184 women received",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      or an AI rather than surgery due to comorbidities (35 percent), age (15 percent), and patient choice (40 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?12/58/13226/abstract/53\">",
"       53",
"      </a>",
"      ]. The mean age of patients was 84 years (range, 75 to 89 years). Fifty percent had T2-sized cancers and 22 percent had node involvement. With a mean follow-up time of 2.6 years, the main findings were:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Observed times to response and progression were similar in those receiving",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      or an AI.",
"     </li>",
"     <li>",
"      Endocrine therapy resulted in an initial response rate of 58 percent and stable disease in 11 percent.",
"     </li>",
"     <li>",
"      Although 65 percent died during follow-up, only 14 percent died of breast cancer.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20723014\">",
"    <span class=\"h3\">",
"     Primary radiation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;We do not administer RT as sole treatment of breast cancer in medically frail patients. Moderately high doses would generally be required to control locally advanced breast cancer in the absence of surgery, which would increase the risks of local toxicity.",
"   </p>",
"   <p>",
"    There are only limited data on the role of RT as primary treatment (without surgery) and no randomized trials have been performed. The available data suggest that long-term results following primary RT are inferior to surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13226/abstract/54,55\">",
"     54,55",
"    </a>",
"    ]. As an example, in a study of 514 women, women who underwent primary RT had lower five- and ten-year survivals compared to women who underwent lumpectomy (68 and 43 percent versus 85 and 75 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/58/13226/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?25/52/26437?source=see_link\">",
"       \"Patient information: Early stage breast cancer treatment in postmenopausal women (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Breast cancer is a major health concern in the geriatric population. However, older women often are treated less aggressively than younger women, even after controlling for confounding factors, such as comorbidity, social support, and functional status. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with breast cancer over age 65 years, a comprehensive geriatric assessment (CGA) (",
"      <a class=\"graphic graphic_table graphicRef71535 \" href=\"UTD.htm?6/54/7020\">",
"       table 2",
"      </a>",
"      ) may help physicians develop a coordinated plan for breast cancer treatment. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Comprehensive geriatric assessment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The treatment approach to medically fit older women with newly diagnosed non-metastatic breast cancer is similar to that of younger women. This consists of surgery to the breast and axilla, RT if applicable, and systemic treatment if indicated. (See",
"      <a class=\"local\" href=\"#H184391652\">",
"       'Medically fit'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If able, medically frail patients should proceed with surgery.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      We suggest observation rather than adjuvant treatment following surgery, especially if their life expectancy is limited (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      For patients who desire subsequent treatment, adjuvant therapy can be administered using an approach similar to that used for medically frail patients. (See",
"      <a class=\"local\" href=\"#H1725156589\">",
"       'Patients who are not surgical candidates'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For medically frail women with breast cancer who are not candidates for surgery (including those who decline surgery) and desire treatment despite the risk of toxicity associated with systemic therapy, we take the patient&rsquo;s tumor characteristics in to consideration (see",
"      <a class=\"local\" href=\"#H184391833\">",
"       'Medically frail'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For patients with hormone receptor-positive breast cancer, we offer primary endocrine therapy rather than chemotherapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1725156350\">",
"       'Primary endocrine therapy in hormone receptor-positive breast cancer'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with hormone receptor-negative disease, we suggest single agent chemotherapy rather than combination chemotherapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/20/32072?source=see_link\">",
"       \"Systemic treatment for metastatic breast cancer: Selection of chemotherapy regimen\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with HER2-positive disease (regardless of hormone receptor-status), we suggest single agent HER2-directed therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). An alternative option would be to add a HER2-directed agent to systemic therapy, provided patients are aware of the additional risks associated with combined treatment. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/43/22202?source=see_link&amp;anchor=H111523989#H111523989\">",
"       \"Systemic treatment for metastatic breast cancer: Molecular targeted therapy\", section on 'HER2-directed therapy'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Medically frail women with a limited life expectancy and those who wish to avoid treatment and the associated risk of toxicity should be offered supportive care and referral for palliative care services. (See",
"      <a class=\"local\" href=\"#H184391833\">",
"       'Medically frail'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For medically frail patients who are not candidates for surgery, we do not recommend primary RT (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H20723014\">",
"       'Primary radiation therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13226/abstract/1\">",
"      Wyld L, Garg DK, Kumar ID, et al. Stage and treatment variation with age in postmenopausal women with breast cancer: compliance with guidelines. Br J Cancer 2004; 90:1486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13226/abstract/2\">",
"      Enger SM, Thwin SS, Buist DS, et al. Breast cancer treatment of older women in integrated health care settings. J Clin Oncol 2006; 24:4377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13226/abstract/3\">",
"      Lavelle K, Todd C, Moran A, et al. Non-standard management of breast cancer increases with age in the UK: a population based cohort of women &gt; or =65 years. Br J Cancer 2007; 96:1197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13226/abstract/4\">",
"      Cyr A, Gillanders WE, Aft RL, et al. Breast cancer in elderly women (&ge; 80 years): variation in standard of care? J Surg Oncol 2011; 103:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13226/abstract/5\">",
"      Bastiaannet E, Liefers GJ, de Craen AJ, et al. Breast cancer in elderly compared to younger patients in the Netherlands: stage at diagnosis, treatment and survival in 127,805 unselected patients. Breast Cancer Res Treat 2010; 124:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13226/abstract/6\">",
"      Gennari R, Curigliano G, Rotmensz N, et al. Breast carcinoma in elderly women: features of disease presentation, choice of local and systemic treatments compared with younger postmenopasual patients. Cancer 2004; 101:1302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13226/abstract/7\">",
"      Diab SG, Elledge RM, Clark GM. Tumor characteristics and clinical outcome of elderly women with breast cancer. J Natl Cancer Inst 2000; 92:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13226/abstract/8\">",
"      Pierga JY, Girre V, Laurence V, et al. Characteristics and outcome of 1755 operable breast cancers in women over 70 years of age. Breast 2004; 13:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13226/abstract/9\">",
"      Rodrigues NA, Dillon D, Carter D, et al. Differences in the pathologic and molecular features of intraductal breast carcinoma between younger and older women. Cancer 2003; 97:1393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13226/abstract/10\">",
"      Grann VR, Troxel AB, Zojwalla NJ, et al. Hormone receptor status and survival in a population-based cohort of patients with breast carcinoma. Cancer 2005; 103:2241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13226/abstract/11\">",
"      Bacchi LM, Corpa M, Santos PP, et al. Estrogen receptor-positive breast carcinomas in younger women are different from those of older women: a pathological and immunohistochemical study. Breast 2010; 19:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13226/abstract/12\">",
"      Poltinnikov IM, Rudoler SB, Tymofyeyev Y, et al. Impact of Her-2 Neu overexpression on outcome of elderly women treated with wide local excision and breast irradiation for early stage breast cancer: an exploratory analysis. Am J Clin Oncol 2006; 29:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13226/abstract/13\">",
"      Honma N, Sakamoto G, Akiyama F, et al. Breast carcinoma in women over the age of 85: distinct histological pattern and androgen, oestrogen, and progesterone receptor status. Histopathology 2003; 42:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13226/abstract/14\">",
"      Anderson WF, Pfeiffer RM, Dores GM, Sherman ME. Comparison of age distribution patterns for different histopathologic types of breast carcinoma. Cancer Epidemiol Biomarkers Prev 2006; 15:1899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13226/abstract/15\">",
"      Yancik R, Ries LG, Yates JW. Breast cancer in aging women. A population-based study of contrasts in stage, surgery, and survival. Cancer 1989; 63:976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13226/abstract/16\">",
"      Goodwin JS, Hunt WC, Samet JM. Determinants of cancer therapy in elderly patients. Cancer 1993; 72:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13226/abstract/17\">",
"      Schonberg MA, Marcantonio ER, Ngo L, et al. Causes of death and relative survival of older women after a breast cancer diagnosis. J Clin Oncol 2011; 29:1570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13226/abstract/18\">",
"      Extermann M, Balducci L, Lyman GH. What threshold for adjuvant therapy in older breast cancer patients? J Clin Oncol 2000; 18:1709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13226/abstract/19\">",
"      Extermann M, Aapro M. Assessment of the older cancer patient. Hematol Oncol Clin North Am 2000; 14:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13226/abstract/20\">",
"      Patnaik JL, Byers T, Diguiseppi C, et al. The influence of comorbidities on overall survival among older women diagnosed with breast cancer. J Natl Cancer Inst 2011; 103:1101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13226/abstract/21\">",
"      Vaeth PA, Satariano WA, Ragland DR. Limiting comorbid conditions and breast cancer stage at diagnosis. J Gerontol A Biol Sci Med Sci 2000; 55:M593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13226/abstract/22\">",
"      Fleming ST, Sabatino SA, Kimmick G, et al. Developing a claim-based version of the ACE-27 comorbidity index: a comparison with medical record review. Med Care 2011; 49:752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13226/abstract/23\">",
"      Braithwaite D, Satariano WA, Sternfeld B, et al. Long-term prognostic role of functional limitations among women with breast cancer. J Natl Cancer Inst 2010; 102:1468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13226/abstract/24\">",
"      Rothman MD, Leo-Summers L, Gill TM. Prognostic significance of potential frailty criteria. J Am Geriatr Soc 2008; 56:2211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13226/abstract/25\">",
"      Ferrucci L, Guralnik JM, Studenski S, et al. Designing randomized, controlled trials aimed at preventing or delaying functional decline and disability in frail, older persons: a consensus report. J Am Geriatr Soc 2004; 52:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13226/abstract/26\">",
"      Valero S, Migeot V, Bouche G. Who needs a Comprehensive Geriatric Assessment? A French Onco-Geriatric Screening tool. J Geriatric Oncol 2011; 2:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13226/abstract/27\">",
"      Hurria A, Gupta S, Zauderer M, et al. Developing a cancer-specific geriatric assessment: a feasibility study. Cancer 2005; 104:1998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13226/abstract/28\">",
"      Audisio RA, Bozzetti F, Gennari R, et al. The surgical management of elderly cancer patients; recommendations of the SIOG surgical task force. Eur J Cancer 2004; 40:926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13226/abstract/29\">",
"      Sandison AJ, Gold DM, Wright P, Jones PA. Breast conservation or mastectomy: treatment choice of women aged 70 years and older. Br J Surg 1996; 83:994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13226/abstract/30\">",
"      Sweeney C, Schmitz KH, Lazovich D, et al. Functional limitations in elderly female cancer survivors. J Natl Cancer Inst 2006; 98:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13226/abstract/31\">",
"      Mano M, Fraser G, McIlroy P, et al. Locally advanced breast cancer in octogenarian women. Breast Cancer Res Treat 2005; 89:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13226/abstract/32\">",
"      Deutsch M. Radiotherapy after lumpectomy for breast cancer in very old women. Am J Clin Oncol 2002; 25:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13226/abstract/33\">",
"      Veronesi U, Luini A, Del Vecchio M, et al. Radiotherapy after breast-preserving surgery in women with localized cancer of the breast. N Engl J Med 1993; 328:1587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13226/abstract/34\">",
"      Smith BD, Gross CP, Smith GL, et al. Effectiveness of radiation therapy for older women with early breast cancer. J Natl Cancer Inst 2006; 98:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13226/abstract/35\">",
"      Pinder MC, Duan Z, Goodwin JS, et al. Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J Clin Oncol 2007; 25:3808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13226/abstract/36\">",
"      Muss HB, Woolf S, Berry D, et al. Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer. JAMA 2005; 293:1073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13226/abstract/37\">",
"      Du XL, Osborne C, Goodwin JS. Population-based assessment of hospitalizations for toxicity from chemotherapy in older women with breast cancer. J Clin Oncol 2002; 20:4636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13226/abstract/38\">",
"      Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365:1687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13226/abstract/39\">",
"      Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Peto R, Davies C, et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 2012; 379:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13226/abstract/40\">",
"      Ryberg M, Nielsen D, Cortese G, et al. New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients. J Natl Cancer Inst 2008; 100:1058.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13226/abstract/41\">",
"      Jones S, Holmes FA, O'Shaughnessy J, et al. Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735. J Clin Oncol 2009; 27:1177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13226/abstract/42\">",
"      Crivellari D, Bonetti M, Castiglione-Gertsch M, et al. Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VII. J Clin Oncol 2000; 18:1412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13226/abstract/43\">",
"      De Maio E, Gravina A, Pacilio C, et al. Compliance and toxicity of adjuvant CMF in elderly breast cancer patients: a single-center experience. BMC Cancer 2005; 5:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13226/abstract/44\">",
"      Muss HB, Berry DA, Cirrincione CT, et al. Adjuvant chemotherapy in older women with early-stage breast cancer. N Engl J Med 2009; 360:2055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13226/abstract/45\">",
"      Slamon D, Eiermann W, Robert N, et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 2011; 365:1273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13226/abstract/46\">",
"      Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Davies C, Godwin J, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 2011; 378:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13226/abstract/47\">",
"      Dowsett M, Cuzick J, Ingle J, et al. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol 2010; 28:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13226/abstract/48\">",
"      Hind D, Wyld L, Beverley CB, Reed MW. Surgery versus primary endocrine therapy for operable primary breast cancer in elderly women (70 years plus). Cochrane Database Syst Rev 2006; :CD004272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13226/abstract/49\">",
"      Chakrabarti J, Kenny FS, Syed BM, et al. A randomised trial of mastectomy only versus tamoxifen for treating elderly patients with operable primary breast cancer-final results at 20-year follow-up. Crit Rev Oncol Hematol 2011; 78:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13226/abstract/50\">",
"      Johnston SJ, Kenny FS, Syed BM, et al. A randomised trial of primary tamoxifen versus mastectomy plus adjuvant tamoxifen in fit elderly women with invasive breast carcinoma of high oestrogen receptor content: long-term results at 20 years of follow-up. Ann Oncol 2012; 23:2296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13226/abstract/51\">",
"      PACE participants, Audisio RA, Pope D, et al. Shall we operate? Preoperative assessment in elderly cancer patients (PACE) can help. A SIOG surgical task force prospective study. Crit Rev Oncol Hematol 2008; 65:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13226/abstract/52\">",
"      Balakrishnan A, Ravichandran D. Early operable breast cancer in elderly women treated with an aromatase inhibitor letrozole as sole therapy. Br J Cancer 2011; 105:1825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13226/abstract/53\">",
"      Wink CJ, Woensdregt K, Nieuwenhuijzen GA, et al. Hormone treatment without surgery for patients aged 75 years or older with operable breast cancer. Ann Surg Oncol 2012; 19:1185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13226/abstract/54\">",
"      Calle R, Pilleron JP, Schlienger P, Vilcoq JR. Conservative management of operable breast cancer: ten years experience at the Foundation Curie. Cancer 1978; 42:2045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/58/13226/abstract/55\">",
"      Weissberg JB, Prosnitz LR. Treatment of early breast cancer with primary radiation therapy: rationale, results, and techniques. Bull N Y Acad Med 1982; 58:203.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 757 Version 20.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-183.166.191.243-382E3F64B8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_58_13226=[""].join("\n");
var outline_f12_58_13226=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H28\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H184390246\">",
"      TREATMENT PATTERNS OF OLDER WOMEN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      FACTORS THAT AFFECT TREATMENT DECISIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H518871776\">",
"      Tumor biology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H518872214\">",
"      General health status",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Life expectancy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Comorbidity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H518872251\">",
"      - Functional status",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H518874633\">",
"      - Frailty",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      COMPREHENSIVE GERIATRIC ASSESSMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      TREATMENT APPROACH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H184391652\">",
"      MEDICALLY FIT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Breast surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Management of the axilla",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Role of radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1734265603\">",
"      Adjuvant therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H184392052\">",
"      - Chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H518876098\">",
"      Anthracycline-containing regimens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H518876105\">",
"      Docetaxel plus cyclophosphamide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1734265746\">",
"      Other regimens",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H518875665\">",
"      - HER2-directed agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H518875797\">",
"      - Endocrine therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H184391833\">",
"      MEDICALLY FRAIL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1725156207\">",
"      Surgical candidates",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20722981\">",
"      - Surgery versus primary endocrine therapy in women with hormone receptor-positive disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1725156589\">",
"      Patients who are not surgical candidates",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1725156350\">",
"      - Primary endocrine therapy in hormone receptor-positive breast cancer",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20723014\">",
"      - Primary radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/757\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/757|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?25/40/26252\" title=\"table 1\">",
"      Charlson risk index",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/54/7020\" title=\"table 2\">",
"      Comprehensive geriatric assessm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/27/2492\" title=\"table 3\">",
"      Self administered CGA tool",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/56/42892\" title=\"table 4\">",
"      Recom Adj Sys Rx in Older women with br ca",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?31/54/32621\" title=\"table 5\">",
"      Epirub cum dose cardiotox",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/43/2750\" title=\"table 6\">",
"      TC regimen for breast cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/27/12728?source=related_link\">",
"      Accelerated partial breast irradiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/4/37961?source=related_link\">",
"      Adjuvant chemotherapy for hormone receptor-positive or negative, HER2-negative breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/40/20106?source=related_link\">",
"      Adjuvant endocrine therapy for hormone receptor-positive breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/7/11384?source=related_link\">",
"      Adjuvant medical therapy for HER2-positive breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/42/31402?source=related_link\">",
"      Breast conserving therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/46/41706?source=related_link\">",
"      Cardiotoxicity of anthracycline-like chemotherapy agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/12/40138?source=related_link\">",
"      Cardiotoxicity of nonanthracycline cancer chemotherapy agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/56/41864?source=related_link\">",
"      Comprehensive geriatric assessment for patients with cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/7/28792?source=related_link\">",
"      Frailty",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/44/43719?source=related_link\">",
"      Functional problems in the patient with cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/47/19194?source=related_link\">",
"      Hormone receptors in breast cancer: Clinical utility and guideline recommendations to improve test accuracy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/52/42825?source=related_link\">",
"      Management of the regional lymph nodes in breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/18/12586?source=related_link\">",
"      Mastectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/31/1529?source=related_link\">",
"      Neoadjuvant systemic therapy for breast cancer: Response, subsequent treatment, and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/40/35466?source=related_link\">",
"      Neoadjuvant therapy for breast cancer: Rationale, pretreatment evaluation, and therapeutic options",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/46/19177?source=related_link\">",
"      Overview of the treatment of newly diagnosed, non-metastatic breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/6/29801?source=related_link\">",
"      Palliative care: Benefits, services, and models of care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/42/16040?source=related_link\">",
"      Pathology of breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?25/52/26437?source=related_link\">",
"      Patient information: Early stage breast cancer treatment in postmenopausal women (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/3/41017?source=related_link\">",
"      Postmastectomy chest wall irradiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/55/42873?source=related_link\">",
"      Radiation techniques for locally advanced breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/7/11385?source=related_link\">",
"      Role of radiation therapy in breast conservation therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/47/36602?source=related_link\">",
"      Sentinel lymph node dissection for breast cancer: Indications and outcomes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/42/10922?source=related_link\">",
"      Systemic chemotherapy for cancer in elderly persons",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/43/22202?source=related_link\">",
"      Systemic treatment for metastatic breast cancer: Molecular targeted therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/20/32072?source=related_link\">",
"      Systemic treatment for metastatic breast cancer: Selection of chemotherapy regimen",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/46/39657?source=related_link\">",
"      Techniques of breast and chest wall irradiation for early stage breast cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_58_13227="Accuracy US in Dx IBD";
var content_f12_58_13227=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F73338&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F73338&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Ultrasonography: sensitivity and specifity in the detection of inflammatory bowel disease",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Sensitivity, percent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Specificity, percent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Number of patients",
"       </td>",
"       <td class=\"subtitle1\">",
"        Study",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        70",
"       </td>",
"       <td>",
"        93",
"       </td>",
"       <td>",
"        32",
"       </td>",
"       <td>",
"        Pradel, JA, et al 1997",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        88",
"       </td>",
"       <td>",
"        93",
"       </td>",
"       <td>",
"        38",
"       </td>",
"       <td>",
"        Faure, C, et al 1997",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        90",
"       </td>",
"       <td>",
"        94",
"       </td>",
"       <td>",
"        240",
"       </td>",
"       <td>",
"        Bozkurt, T, et al 1994",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        94",
"       </td>",
"       <td>",
"        67",
"       </td>",
"       <td>",
"        118",
"       </td>",
"       <td>",
"        Reimund, JM, et al 1999",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        84",
"       </td>",
"       <td>",
"        97",
"       </td>",
"       <td>",
"        57",
"       </td>",
"       <td>",
"        Khaw, KT, et al 1990",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_58_13227=[""].join("\n");
var outline_f12_58_13227=null;
var title_f12_58_13228="Diagnostic criteria cluster headache";
var content_f12_58_13228=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F80843&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F80843&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    ICHD-2 diagnostic criteria for cluster headache",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        A. At least five headache attacks fulfilling criteria B through D:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        B. Severe or very severe unilateral orbital, supraorbital, and/or temporal headache attacks, which last untreated for 15 to 180 minutes. During part (but less than half) of the time course of the cluster headache, attacks may be less severe, less frequent, or of shorter or longer duration.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        C. The headache is accompanied by at least one of the following symptoms:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        1. Ipsilateral conjunctival injection or lacrimation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        2. Ipsilateral nasal congestion and/or rhinorrhea",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        3. Ipsilateral eyelid edema",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        4. Ipsilateral forehead and facial sweating",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        5. Ipsilateral miosis and/or ptosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        6. A sense of restlessness and agitation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        D. The attacks have a frequency from one every other day to eight per day.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        E. History and physical and neurologic examinations do not suggest any other disorder, and/or such a disorder is ruled out by appropriate investigations, or such disorder is present but attacks do not occur for the first time in close temporal relation to the disorder.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Episodic cluster headache:",
"        </strong>",
"        At least two cluster periods lasting seven days to one year separated by pain-free periods lasting one month or longer.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Chronic cluster headache:",
"        </strong>",
"        Attacks occur for more than one year without remission or with remission less than one month.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Probable cluster headache:",
"        </strong>",
"        Attacks fulfilling all but one criteria for cluster headache.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia 2004; 24 Suppl 1:9.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_58_13228=[""].join("\n");
var outline_f12_58_13228=null;
var title_f12_58_13229="T-cell antigen receptor";
var content_f12_58_13229=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F56665&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F56665&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    The T cell antigen receptor",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 411px; height: 258px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The core of the receptor complex is a heterodimer composed of either &alpha; and &beta; chains, or &gamma; and &delta;. These molecules are members of the immunoglobulin gene superfamily. Each contains two immunoglobulin-like domains with intrachain disulfide bridges. The two chains are also disulfide-linked to each other. The cytoplasmic domains of these chains are short, and signaling is carried out by associated molecules.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_58_13229=[""].join("\n");
var outline_f12_58_13229=null;
var title_f12_58_13230="Infectious causes of uveitis";
var content_f12_58_13230=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F61247%7ERHEUM%2F75844%7ERHEUM%2F55902%7ERHEUM%2F64117&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F61247%7ERHEUM%2F75844%7ERHEUM%2F55902%7ERHEUM%2F64117&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Representative infectious causes of uveitis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1\">",
"            Bacterial/spirochetal",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Atypical mycobacteria",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Brucellosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cat scratch disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Leprosy",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Leptospirosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Lyme disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Propionibacterium",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Syphilis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Tuberculosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Whipple's disease",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1\">",
"            Viral",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Chikungunya",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cytomegalovirus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Epstein-Barr",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Herpes simplex",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Herpes zoster",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            HIV-1",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Human T cell leukemia virus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Mumps",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Parechovirus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Rubella",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Rubeola",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Vaccinia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            West Nile virus",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1\">",
"            Fungal",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Aspergillosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Blastomycosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Candidiasis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Coccidioidomycosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cryptococcosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Histoplasmosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Pneumocystis jirovecii (PCP)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Sporotrichosis",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1\">",
"            Parasitic (protozoan/helminthic)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Acanthamoeba",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cystercercosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Onchocerciasis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Toxocariasis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Toxoplasmosis",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Uveitis syndromes confined primarily to the eye",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td>",
"       Acute multifocal placoid pigmentary epitheliopathy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Acute retinal necrosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Birdshot choroidopathy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Fuchs' heterochromic cyclitis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Glaucomatocyclitic crisis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Immune recovery (reconstitution) uveitis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Iridocorneal endothelial syndrome",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Leber's neuroretinitis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Multifocal evanescent white dot syndrome",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Pars planitis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Punctate inner choroidopathy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Serpiginous choroidopathy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Subretinal fibrosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Sympathetic ophthalmia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Trauma",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Systemic immune-mediated causes of uveitis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Ankylosing spondylitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Beh&ccedil;ets disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Blau syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Crohn's disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Drug or hypersensitivity reaction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Interstitial nephritis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Juvenile idiopathic arthritis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Kawasaki's disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Multiple sclerosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neonatal onset multisystem inflammatory disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Psoriatic arthritis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Reactive arthritis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Relapsing polychondritis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sarcoidosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sj&ouml;gren's syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Systemic lupus erythematosus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ulcerative colitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vasculitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vitiligo",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vogt Koyanagi Harada syndrome",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Masquerade syndromes that mimic uveitis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Giant retinal tears",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ischemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Leukemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lymphoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ocular melanoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pigmentary dispersion syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Retinitis pigmentosa",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Retinoblastoma",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_58_13230=[""].join("\n");
var outline_f12_58_13230=null;
var title_f12_58_13231="Normal postoperative UGI series after gastric plication";
var content_f12_58_13231=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F58843&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F58843&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Normal postoperative upper gastrointestinal (UGI) series after gastric plication",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 408px; height: 304px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This is an upper GI image after greater curve plication, which looks similar to a sleeve gastrectomy on x-ray.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_58_13231=[""].join("\n");
var outline_f12_58_13231=null;
